

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: SHERATON SAN DIEGO HOTEL AND MARINA
1380 HARBOR ISLAND DRIVE
SAN DIEGO, CALIFORNIA

DATE: WEDNESDAY, JUNE 22, 2011
4 P.M.

REPORTER: BETH C. DRAIN, CSR
CSR. NO. 7152

BRS FILE NO.: 88081

BARRISTERS' REPORTING SERVICE

I N D E X

ITEM DESCRIPTION	PAGE NO.
1. CALL TO ORDER.	5
2. PLEDGE OF ALLEGIANCE.	8
3. ROLL CALL.	8
REPORTS & DISCUSSION ITEMS	
4. CHAIRMAN'S REPORT.	
5. PRESIDENT'S REPORT.	
ACTION ITEMS	
6. CONSIDERATION OF CANDIDATES FOR CHAIR OF THE GOVERNING BOARD OF CIRM, INCLUDING ELECTION AND COMPENSATION OF NEW CHAIR.	43
CLOSED SESSION (NOT REPORTED)	76
PUBLIC REPORT OF ANY ACTION TAKEN DURING CLOSED SESSION.	
ACTION ITEMS	
8. CONSIDERATION OF MINUTES FROM PREVIOUS BOARD MEETING.	
9. CONSIDERATION OF STANDARDS WORKING GROUP RESOLUTION ON U.S. CLINICAL TRIALS.	
10. CONSIDERATION OF REPORT REGARDING IOM STUDY.	85
11. CONSIDERATION OF STAFF RECOMMENDATION TO CORRECT THE AMOUNT OF THE GRANT AWARD APPROVED BY THE BOARD FOR TR2-01794 UNDER THE EARLY TRANSLATIONAL II RFA.	

BARRISTERS' REPORTING SERVICE

I N D E X (CONT'D.)

PAGE NO.

12. CONSIDERATION OF RE-APPOINTMENT OF GRANTS WORKING GROUP MEMBERS WITH EXPIRING TERMS

13. CONSIDERATION OF PROCESS FOR OBTAINING SUPPLEMENTAL INFORMATION FROM APPLICANTS FOR DISEASE TEAM AND CLINICAL TRIAL AWARDS.

14. CONSIDERATION OF RECOMMENDATIONS FROM GOVERNANCE SUBCOMMITTEE REGARDING THE FOLLOWING:

- A. MEMO FROM BOARD COUNSEL SUMMARIZING AMENDMENTS TO INTERNAL GOVERNANCE POLICY - AMENDMENTS
- B. CODE OF CONDUCT
- C. CONSIDERATION OF CONTRACTS ABOVE \$250,000, BUT BELOW \$500,000, INCLUDING THE MITCHELL GROUP, KUTIR CORPORATION, AND NANCY KOCH.

15. CONSIDERATION OF PROPOSAL FOR FUNDING EXTENSION TO TRAINING II AWARDS. 10

16. CONSIDERATION OF PROPOSAL FOR FUNDING EXTENSION TO BRIDGES TO STEM CELLS AWARDS. 28

17. CONSIDERATION OF CONCEPT PROPOSAL FOR NEW FACULTY PHYSICIAN SCIENTIST TRANSLATIONAL RESEARCH AWARD.

18. CONSIDERATION OF CONCEPT CLEARANCE FOR PROPOSED OPPORTUNITY FUND PROGRAM.

19. CONSIDERATION OF AUGMENTATION OF BUDGET OF THE OFFICE OF THE CHAIR TO FUND, AS NECESSARY, CONTRACT FOR FEDERAL GOVERNMENTAL RELATIONS SUPPORT.

BARRISTERS' REPORTING SERVICE

I N D E X (CONT'D)

PAGE NO.

20. CONSIDERATION OF RECOMMENDATIONS FROM LEGISLATIVE SUBCOMMITTEE REGARDING THE FOLLOWING:
- A. POSITION ON US SENATE BILL 23 AND H.R. 1249.
 - B. POSITION ON CALIFORNIA AB 190.
 - C. AMENDMENT TO BOARD BYLAWS TO AUTHORIZE LEGISLATIVE SUBCOMMITTEE TO TAKE ACTION, BY A TWO-THIRDS VOTE, BETWEEN BOARD MEETINGS WITH RESPECT TO STATE AND FEDERAL LEGISLATION.
 - D. PROPOSED ADDITIONAL AGENDA ITEM - CONSIDERATION OF H.R. 1862 (THE REGENERATIVE MEDICINE PROMOTION ACT OF 2011
21. CONSIDERATION OF POSITION DESCRIPTIONS FOR CHIEF FINANCIAL OFFICER AND DIRECTOR OF PUBLIC COMMUNICATIONS.
22. SWEARING IN OF NEW CHAIR
23. CONSIDERATION OF RESOLUTION HONORING ROBERT N. KLEIN FOR HIS SERVICE TO CIRM, STEM CELL RESEARCH AND CALIFORNIA PATIENTS.
24. PROPOSED ADDITIONAL AGENDA ITEM - CONSIDERATION OF CREATION OF INTELLECTUAL PROPERTY SUBCOMMITTEE AND APPOINTMENT OF SUBCOMMITTEE LEADERSHIP AND MEMBERS.
- DISCUSSION ITEMS
25. PUBLIC COMMENT. 89

BARRISTERS' REPORTING SERVICE

1 SAN DIEGO, CALIFORNIA; WEDNESDAY, JUNE 22, 2011

2 4 P.M.

3
4 CHAIRMAN KLEIN: IF WE COULD CALL THE
5 MEETING TO ORDER, WE'RE GOING TO SEE HOW WE ARE ON A
6 QUORUM. GOOD AFTERNOON. WE'RE GOING TO TAKE A
7 QUICK COUNT HERE AND SEE HOW WE'RE DOING ON A
8 QUORUM. IN ORDER TO PROVIDE THE TRAILING MEMBERS OF
9 THE BOARD WHO ARE IN TRANSIT WITH A LITTLE TIME, WE
10 THOUGHT WE'D TAKE UP A COUPLE OF ITEMS ON THE AGENDA
11 WHICH WE EXPECT ARE NOT CONTROVERSIAL BECAUSE
12 THEY'VE BEEN SUCH HUGE SUCCESSES TO DATE. BY DOING
13 SO, WE'LL EFFECTIVELY USE SOME TIME THAT OTHERWISE
14 WE MAY DESPERATELY NEED IN GETTING THROUGH THIS
15 AGENDA.

16 SO IF THE COUNSEL WILL TELL ME HOW WE'RE
17 DOING ON A QUORUM.

18 MR. HARRISON: WE HAVE A QUORUM IN THE
19 ROOM CURRENTLY.

20 CHAIRMAN KLEIN: WE HAVE A QUORUM. AND WE
21 WILL PROCEED. WE'RE GOING TO PROCEED WITH, FIRST,
22 THE TRAINING GRANT ITEM. I WOULD LIKE TO, THOUGH,
23 INTRODUCE A NEW MEMBER OF THE BOARD. DR., THIS IS
24 JURIS DOCTORATE, STEPHEN JUELSGAARD, WHO IS TO THE
25 END OF THE PODIUM ON MY RIGHT. STEPHEN WAS MOST

BARRISTERS' REPORTING SERVICE

1 RECENTLY THE EXECUTIVE VICE PRESIDENT, SECRETARY,
2 AND CHIEF COMPLIANCE OFFICER OF GENENTECH. HE
3 REPORTED DIRECTLY TO GENENTECH'S CEO, ART LEVINSON,
4 RESPONSIBLE FOR GENENTECH'S CORPORATE LAW,
5 INTELLECTUAL PROPERTY, GOVERNMENT AFFAIRS, FEDERAL
6 AND STATE, HUMAN RESOURCES, HEALTH COMPLIANCE
7 GROUPS, AS WELL AS THE BUSINESS SERVICES GROUPS AND
8 THE STRATEGIC FACILITIES PLANNING GROUP.

9 EXTRAORDINARY BODY OF KNOWLEDGE AND
10 EXPERIENCE THAT HE BRINGS TO THE BOARD. I WILL
11 ADDRESS THIS EXPERIENCE LATER. IN OUR OPPORTUNITY
12 TO CAPTURE HIS EXPERIENCE, HE JOINED GENENTECH IN
13 1985 AS CORPORATE COUNSEL AND THEN MADE HIS WAY UP
14 THROUGH THAT ORGANIZATION. HE TEACHES CURRENTLY
15 PART TIME AT STANFORD LAW SCHOOL, AND HE'S ON THE
16 BOARD OF DIRECTORS OF A PRIVATE MEDICAL DEVICE
17 COMPANY.

18 HE HAS A DOCTORATE OF VETERINARY MEDICINE
19 DEGREE IN ADDITION TO HIS JURIS DOCTORATE, SO I
20 SHOULD SAY HE HAS BOTH A DEGREE IN VETERINARY
21 MEDICINE AS WELL AS THE JURIS DOCTORATE AND A
22 MASTER'S DEGREE AS WELL IN VETERINARY CLINICAL
23 SCIENCES FROM IOWA STATE UNIVERSITY. AGAIN, HIS LAW
24 DEGREE WAS FROM STANFORD LAW SCHOOL.

25 IN CONVENING THE MEETING TODAY AS WELL, I

BARRISTERS' REPORTING SERVICE

1 WOULD LIKE TO SAY THAT WE ARE GOING TO HAVE THE
2 CHAIRMAN'S REPORT AND THE PRESIDENT'S REPORT TO
3 BEGIN THE DAY TOMORROW SO THAT WE PRESERVE THE
4 MAXIMUM AMOUNT OF TIME THIS AFTERNOON AND EVENING TO
5 DEAL WITH THE SELECTION OF A NEW CHAIRMAN. BUT IN
6 THAT PROCESS, I WOULD LIKE TO INDICATE THAT WHILE A
7 NUMBER OF INDIVIDUALS HAVE EXPRESSED THANKS TO ME,
8 AND I APPRECIATE THE PERSONAL NOTES, THEY'RE VERY
9 EXTREMELY GENEROUS, THERE IS A PERSON THAT WE'VE
10 NEVER REALLY RECOGNIZED HERE AS A MAJOR CONTRIBUTOR.
11 AND I WOULD LIKE TO TAKE A MOMENT TO ASK THAT WE
12 GIVE A ROUND OF APPLAUSE TO MY WIFE, DANIELLE.

13 (APPLAUSE.)

14 CHAIRMAN KLEIN: SO WHEN WE'RE STRETCHING
15 THE HOURS TO GET THINGS DONE AND THERE'S NO STAFF
16 BECAUSE IT'S A WEEKEND AND IT'S LATE AT NIGHT, YOU
17 KNOW, DANIELLE HAS BEEN AN EXTRAORDINARY PARTNER IN
18 ADVANCING THIS MISSION TO WHICH SHE IS DEEPLY
19 DEDICATED. SO REALLY APPRECIATE THE WONDERFUL
20 PARTNERSHIP WITH WHICH SHE HAS HELPED ME THROUGH
21 THIS CHAIRMANSHIP.

22 AND, DR. TROUNSON, I INDICATED THAT WE'RE
23 GOING TO DO THE PRESIDENT'S AND CHAIRMAN'S REPORT
24 TOMORROW MORNING, AS I DISCUSSED WITH YOU WAS A
25 POSSIBILITY, TO PRESERVE THE MAXIMUM TIME FOR THE

BARRISTERS' REPORTING SERVICE

1 DISCUSSION OF THE POTENTIAL CHAIRMAN.

2 SO WHILE WE'RE WAITING FOR A COUPLE
3 ADDITIONAL INDIVIDUALS, WE'RE GOING TO FIRST THANK
4 EVERYONE, BUT AS MELISSA KING APPROPRIATELY TELLS
5 ME, WE WILL AT LEAST GET THOSE THAT ARE CURRENTLY
6 HERE ON THE ROLL, DO THE PLEDGE OF ALLEGIANCE, AND
7 THEN WE WILL THANK THE PEOPLE OF SAN DIEGO AND OUR
8 BOARD MEMBERS, INCLUDING DUANE ROTH, I THINK DR.
9 BRENNER IS GOING TO BE HERE, DR. BLOOM IS HERE, DR.
10 VUORI IS HERE TO MY FAR RIGHT. IT'S A WONDERFUL
11 PLACE TO BE. IT'S A PHENOMENALLY BEAUTIFUL DAY, AND
12 WE'RE VERY PRIVILEGED TO BE HERE. SO THANK YOU.

13 COULD YOU TAKE THE ROLL, PLEASE.

14 MS. KING: BEFORE I DO THAT, I'D LIKE TO
15 LEAD THE BOARD IN THE PLEDGE OF ALLEGIANCE. SO IF
16 EVERYONE PRESENT COULD PLEASE STAND IF YOU ARE ABLE.

17 (THE PLEDGE OF ALLEGIANCE.)

18 MS. KING: CALLING THE ROLL, ROBERT PRICE
19 FOR ROBERT BIRGENEAU.

20 DR. PRICE: HERE.

21 MS. KING: FLOYD BLOOM.

22 DR. BLOOM: HERE.

23 MS. KING: DAVID BRENNER. JACOB LEVIN FOR
24 SUSAN BRYANT.

25 DR. LEVIN: HERE.

BARRISTERS' REPORTING SERVICE

1 MS. KING: MARCY FEIT. MICHAEL FRIEDMAN.
2 DR. FRIEDMAN: HERE.
3 MS. KING: LEEZA GIBBONS. MICHAEL
4 GOLDBERG.
5 MR. GOLDBERG: HERE.
6 MS. KING: SAM HAWGOOD. STEPHEN
7 JUELSGAARD.
8 DR. JUELSGAARD: HERE.
9 MS. KING. BOB KLEIN.
10 CHAIRMAN KLEIN: HERE.
11 MS. KING: SHERRY LANSING.
12 MS. LANSING: HERE.
13 MS. KING: TED LOVE.
14 DR. LOVE: HERE.
15 MS. KING: BERTRAM LUBIN. SHLOMO MELMED.
16 DR. MELMED: HERE.
17 MS. KING: PHIL PIZZO. CLAIRE POMEROY.
18 DR. POMEROY: HERE.
19 MS. KING: FRANCISCO PRIETO.
20 DR. PRIETO: HERE.
21 MS. KING: CARMEN PULIAFITO.
22 DR. PULIAFITO: HERE.
23 MS. KING: ROBERT QUINT.
24 DR. QUINT: PRESENT.
25 MS. KING: DUANE ROTH.

BARRISTERS' REPORTING SERVICE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MR. ROTH: HERE.

MS. KING: JOAN SAMUELSON.

MS. SAMUELSON: HERE.

MS. KING: DAVID SERRANO-SEWELL.

MR. SERRANO-SEWELL: HERE.

MS. KING: JEFF SHEEHY.

MR. SHEEHY: HERE.

MS. KING: JON SHESTACK.

MR. SHESTACK: HERE.

MS. KING: OSWALD STEWARD.

DR. STEWARD: HERE.

MS. KING: ART TORRES.

MR. TORRES: HERE.

MS. KING: KRISTINA VUORI.

DR. VUORI: HERE.

MS. KING: EUGENE WASHINGTON.

WE DO HAVE A QUORUM.

CHAIRMAN KLEIN: THANK YOU VERY MUCH. SO
WE'RE GOING TO PROCEED. THE ITEM THAT WE'RE GOING
TO GO TO IS IN YOUR BOOKS AND MATERIALS AT ITEM 15,
AND WE'RE GOING TO FOLLOW THAT WITH ITEM 16.

ON ITEM 15, DR. TROUNSON, MY UNDERSTANDING
IS THAT DR. SAMBRANO WILL BE PRESENTING THAT, ITEM
15 BEING THE FELLOWSHIP TRAINING GRANTS.

DR. TROUNSON: THAT'S CORRECT, CHAIR.

BARRISTERS' REPORTING SERVICE

1 DR. SAMBRANO: MR. CHAIRMAN, MEMBERS OF
2 THE BOARD, MEMBERS OF THE PUBLIC, THE CIRM RESEARCH
3 TRAINING PROGRAM IS A VERY SUCCESSFUL INITIATIVE
4 THAT HAS FUELED THE GROWTH OF THE STEM CELL
5 COMMUNITY IN CALIFORNIA AND FACILITATED THE
6 RECRUITMENT AND RETENTION OF TALENTED RESEARCHERS.
7 SO WE BRING THIS ITEM TO YOU TODAY BECAUSE WE WISH
8 TO PRESERVE THE BENEFIT AND THE GROWING
9 CONTRIBUTIONS OF THIS PROGRAM TO CALIFORNIA AND TO
10 THE MISSION OF CIRM.

11 THIS INITIATIVE WAS INTENDED TO ACHIEVE
12 SEVERAL GOALS FROM THE ONSET: TO TRAIN INDIVIDUALS
13 FROM DIVERSE SCIENTIFIC BACKGROUNDS IN STEM CELL
14 BIOLOGY AND REGENERATIVE MEDICINE, TO EXPAND THE
15 OVERALL POOL OF RESEARCHERS WITH ADVANCED TRAINING
16 AND SPECIALIZED TECHNIQUES AND METHODS, AND TO
17 DIRECTLY SUPPORT RESEARCH AND BASIC TRANSLATIONAL
18 AND PRECLINICAL STUDIES THAT ADVANCE CIRM'S MISSION.

19 THE TRAINING PROGRAM BEGAN IN 2006 UNDER
20 CIRM'S FIRST RFA. AND SO AFTER FIVE YEARS OF
21 SUPPORTING MANY OF THESE PROGRAMS, WE SHOULD FEEL
22 PROUD OF WHAT HAS BEEN ACCOMPLISHED. THE TRAINING
23 PROGRAM OVERALL HAS ACHIEVED VARIOUS CRITERIA OF
24 SUCCESS AND SOME THAT WERE PERHAPS NOT PREDICTED AT
25 FIRST.

BARRISTERS' REPORTING SERVICE

1 THE TRAINING PROGRAM HAS SUPPORTED 17
2 INSTITUTIONS, AT LEAST CURRENTLY, THAT TRAINED ABOUT
3 198 CIRM SCHOLARS PER YEAR AT THE PREDOCTORAL,
4 POSTDOCTORAL, AND CLINICAL LEVELS. THE CIRM
5 SCHOLARS HAVE CONDUCTED STEM CELL RESEARCH ACROSS
6 MORE THAN 200 DISTINCT LABORATORIES AND PRODUCED
7 OVER 455 PUBLICATIONS, MANY IN HIGH-IMPACT JOURNALS.

8 UPON COMPLETING TRAINING, INDIVIDUAL CIRM
9 SCHOLARS HAVE MOVED ON TO FACULTY POSITIONS AT TOP
10 UNIVERSITIES. THEY HAVE ACQUIRED POSITIONS IN
11 BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES OR GONE
12 ON TO FURTHER TRAINING AT LABORATORIES OF LEADING
13 STEM CELL SCIENTISTS. MANY PHYSICIAN CIRM SCHOLARS
14 ARE NOW PRACTICING MEDICINE WITH A STRONG KNOWLEDGE
15 BASE OF STEM CELL SCIENCE.

16 IN ADDITION TO TRAINEE SUCCESS, THE
17 PROGRAM HAS SERVED AS A FOCAL POINT FOR STEM CELL
18 RESEARCH AT EACH OF THE TRAINING INSTITUTIONS AND
19 PRODUCED AN ATTRACTIVE RESEARCH ENVIRONMENT THAT HAS
20 CONTRIBUTED TO THE OVERALL RECRUITMENT OF NEW
21 FACULTY AS WELL AS TOP TRAINEES. TOP STUDENTS ARE,
22 IN FACT, CHOOSING CALIFORNIA OVER OTHER STATES
23 BECAUSE OF THIS PROGRAM.

24 THE RESEARCH CONDUCTED BY TRAINEES HAS
25 SPANNED THE SPECTRUM OF BASIC TO PRECLINICAL

BARRISTERS' REPORTING SERVICE

1 RESEARCH AND, IMPORTANTLY, HAS ACCELERATED RESEARCH
2 THROUGH SYNERGY WITH OTHER CIRM-FUNDED PROGRAMS.
3 AND CIRM WOULD LIKE TO CONTINUE THESE SUCCESSFUL
4 PROGRAMS BY EXTENDING THE AWARD PERIOD FOR UP TO
5 THREE YEARS SO THAT THE TRAINING IS NOT INTERRUPTED
6 AND ONGOING CONTRIBUTIONS OF THESE PROGRAM CAN BE
7 RETAINED.

8 AWARDS ARE NORMALLY ADMINISTERED WITH
9 REGULAR MONITORING OF PROGRESS AND COMPLIANCE AS ANY
10 OF THE OTHER CIRM AWARDS ARE. ONGOING FUNDING IS
11 ALWAYS DEPENDENT ON EACH OF THE GRANTEES MEETING
12 THESE OBJECTIVES. WHAT WE LOOK FOR AMONG THE
13 TRAINING PROGRAMS IS A DEMONSTRATION OF SUCCESSFUL
14 TRAINING OUTCOMES FOR EACH OF THE TRAINEE TYPES
15 SUPPORTED, INCLUDING THE ADVANCEMENT OF TRAINEES TO
16 STEM CELL RESEARCH POSITIONS, FACULTY OR OTHERWISE,
17 MAINTAINING REQUIRED STEM CELL BIOLOGY COURSEWORK,
18 HAVING AN ACTIVE INSTITUTIONAL STEM CELL PROGRAM
19 THAT PROVIDES ADEQUATE MENTORSHIP OPPORTUNITIES AND
20 CAREER DEVELOPMENT ACTIVITIES, AND ONGOING
21 COMMITMENT FROM THE INSTITUTION TO SUPPORT THE
22 PROGRAM. EACH PROGRAM IS REVIEWED ON AN ANNUAL
23 BASIS TO ENSURE THAT EACH ONE IS MEETING THESE KEY
24 GOALS.

25 IN ADDITION, WE PROPOSE THAT A SITE VISIT

BARRISTERS' REPORTING SERVICE

1 OF THE PROGRAM THAT INCLUDES MEETING WITH TRAINEES,
2 MENTORS, AND PROGRAM DIRECTORS BE REQUIRED PRIOR TO
3 INITIATING THE EXTENDED AWARD PERIOD.

4 SO WHAT WE ARE REQUESTING IS AN EXTENSION
5 OF EACH OF THE CIRM RESEARCH TRAINING GRANTS FOR A
6 PERIOD OF UP TO THREE YEARS THAT WOULD FOLLOW THE
7 CURRENT ENDING OF THEIR FIRST THREE YEARS, THAT THE
8 FUNDING LEVELS BE MAINTAINED AS ORIGINALLY REQUESTED
9 IN THEIR APPLICATION EXCEPT FOR SOME ADJUSTMENTS
10 THAT WOULD INCLUDE BIENNIAL STIPEND INCREASES FOR
11 THE TRAINEES. SO THE TOTAL AMOUNT REQUESTED IS 46.7
12 MILLION.

13 IN YOUR BOOKS THERE IS A TABLE THAT HAS
14 THE INDIVIDUAL AMOUNTS FOR EACH PROGRAM AND ALSO
15 SHOWS YOU THE FEATURES OF EACH ONE, INCLUDING THE
16 NUMBER OF TRAINEE SLOTS AND SOME OF THE OUTPUT IN
17 TERMS OF PRODUCTIVITY FROM PUBLICATIONS OF THOSE.
18 SO I'M HAPPY TO ADDRESS ANY QUESTIONS YOU MAY HAVE
19 ABOUT THE PROGRAM.

20 CHAIRMAN KLEIN: SO, DR. SAMBRANO, I THINK
21 IT WOULD BE INVALUABLE FOR THE PUBLIC AND THOSE
22 LISTENING ON THE WEBCAST TO KNOW THAT THERE HAVE
23 BEEN, AS YOU REFERENCE, I THINK, SOME EXTRAORDINARY
24 BENEFITS THROUGH THIS PROGRAM. WHILE IN THIS
25 FELLOWSHIP PROGRAM, ONE OF THESE INDIVIDUALS WAS A

BARRISTERS' REPORTING SERVICE

1 CRITICAL PERSON IN DR. CATRIONA JAMIESON'S LAB IN
2 THE DISCOVERIES THAT LED TO THE JAK2 INHIBITOR PAPER
3 THAT WAS PUBLISHED CONCURRENTLY WITH A PAPER FROM
4 HARVARD AND NOW HAS LED TO A PHASE II TRIAL THAT IS
5 UNDER WAY BY TARGEEN. THE INITIAL RESULTS OF THAT
6 WERE SO FAVORABLE, THAT SONOFI-AVENTIS HAS ACTUALLY
7 PURCHASED TARGEEN.

8 SO THAT'S JUST ONE EXAMPLE OF WHERE THESE
9 BRILLIANT YOUNG SCIENTISTS ARE USING THIS KNOWLEDGE
10 IN REAL TIME TO ADVANCE MEDICAL THERAPIES IN
11 DRAMATIC WAYS.

12 I THINK THAT THERE'S A COUPLE OF OTHER
13 EXAMPLES THAT WERE CITED. COULD YOU REVIEW THOSE,
14 PLEASE?

15 DR. SAMBRANO: CERTAINLY. MANY OF YOU
16 MIGHT HAVE HEARD SOME RECENT ADVANCEMENTS IN THE
17 REPROGRAMMING OF IPSC CELLS. AND SO ONE OF THOSE
18 WAS DONE BY A CIRM SCHOLAR WHO IS NOW A FACULTY
19 MEMBER AT THE HARVARD STEM CELL INSTITUTE. HE
20 PUBLISHED WORK ESSENTIALLY DESCRIBING THE USE OF
21 SYNTHETIC MRNA TO REPROGRAM FIBROBLASTS INTO IPSC.
22 THIS TECHNOLOGY HAS BEEN ADOPTED ACTUALLY QUITE
23 BROADLY NOW AND HAS CERTAINLY BEEN AN AREA OF RECENT
24 INTEREST IN THE COMMUNITY.

25 CHAIRMAN KLEIN: AND FOR THOSE OF YOU WHO

BARRISTERS' REPORTING SERVICE

1 LOOK ONLINE AT THE NEW ANNUAL REPORT, WHICH THE
2 BOARD MEMBERS HAVE BEFORE THEM, ON PAGE 40 OF THAT
3 ANNUAL REPORT IS A PICTURE OF THERESA BLANDA, WHO,
4 IN FACT, WITH MYELOFIBROSIS IN A VERY ADVANCED
5 STAGE, WAS TAKEN OFF -- AFTER THIS TREATMENT WAS
6 TAKEN OFF OF THE BONE MARROW TRANSPLANT LIST BECAUSE
7 THE DETECTION OF THE DISEASE REACHED SUCH A LOW
8 LEVEL, THAT THEY NO LONGER ADVISED A BONE MARROW
9 TRANSPLANT.

10 SO TREMENDOUS ADVANCE. WE HAVE TO BE VERY
11 CAUTIOUS AND WATCH OVER A PERIOD OF YEARS TO SEE
12 WHAT THE FOLLOW-UP TELLS US. BUT INITIAL
13 INDICATIONS ARE VERY STRONG THAT SOME REALLY
14 BREAKTHROUGH WORK HAS BEEN CONDUCTED, AND IT IS
15 INTERESTING TO NOTE THAT THERESA WORKS FOR THE L.A.
16 TIMES. AND SOME OF THE INDIVIDUALS REPORTING FOR
17 FOR THE TIMES ARE NOT YET AWARE OF HOW DRAMATIC THE
18 EFFECT OF SOME OF OUR RESEARCH FUNDING HAS BEEN.

19 SO I'D LIKE TO KNOW IS THERE ADDITIONAL
20 QUESTIONS. I THINK JONATHAN SHESTACK HAS A
21 QUESTION.

22 MR. SHESTACK: GIL, I JUST ASK A QUESTION
23 ON THE MECHANICS. SO THIS WOULD BE TO RENEW 16
24 GRANTS, 16 PROGRAMS?

25 DR. SAMBRANO: IT'S 17 PROGRAMS, YES.

BARRISTERS' REPORTING SERVICE

1 MR. SHESTACK: NOW, WAS THERE ANYBODY
2 WHO -- IS THERE ANYBODY WHO APPLIED THE FIRST TIME,
3 DIDN'T MAKE IT, WHO MIGHT HAVE AN OPPORTUNITY TO
4 APPLY FOR A TRAINING PROGRAM, OR DOES THAT REALLY
5 COVER ALL THE FACULTIES IN CALIFORNIA THAT COULD
6 POSSIBLY MOUNT A GOOD APPLICATION?

7 DR. SAMBRANO: SO WE'VE GONE THROUGH TWO
8 ROUNDS OF COMPETITION. SO ESSENTIALLY I THINK WE
9 HAVE COVERED QUITE A BROAD SPECTRUM. I THINK IF
10 THERE WERE MORE PROGRAMS THAT COULD COME IN, THERE'S
11 A POSSIBILITY. I CAN THINK OF MAY BE ONE OR TWO.
12 BUT I THINK THE PURPOSE OF THIS IS REALLY TO NOT
13 HAVE TO SUBJECT THESE CURRENT PROGRAMS THROUGH
14 ANOTHER ROUND OF COMPETITION.

15 MR. SHESTACK: THANK YOU.

16 CHAIRMAN KLEIN: IS THERE --

17 DR. JUELSGAARD: SO OBVIOUSLY THIS IS MY
18 FIRST MEETING, AND I'M VERY NEW TO THIS GROUP AND
19 THERE ARE A LOT OF THINGS I HAVE YET TO LEARN. BUT
20 ONE OF THE -- AND I UNDERSTAND IN TALKING TO DR.
21 LOVE THAT THIS IS AN ITEM THAT WAS BUDGETED FOR THIS
22 YEAR.

23 MR. HARRISON: CHAIR, THIS IS AN ITEM,
24 BECAUSE IT RELATES TO EXISTING GRANTS, WHERE WE
25 SHOULD ADVISE BOARD MEMBERS OF WHO CAN PARTICIPATE

BARRISTERS' REPORTING SERVICE

1 IN THIS DISCUSSION.

2 CHAIRMAN KLEIN: I SPECIFICALLY CALLED ON
3 MR. JUELSGAARD. I DON'T BELIEVE HE HAS A CONFLICT
4 IN THIS MATTER, BUT WHY DON'T YOU LAY OUT THE
5 FRAMEWORK FOR OTHER MEMBERS BEING ABLE TO DISCUSS
6 THIS.

7 MR. HARRISON: AS I SAID, BECAUSE THIS
8 MATTER RELATES TO EXISTING AWARDS, THE MEMBERS WHO
9 CAN PARTICIPATE IN THIS ITEM ARE MEMBERS KLEIN,
10 TORRES, GIBBONS, SAMUELSON, SERRANO-SEWELL, QUINT,
11 SHESTACK, LUBIN, AND LOVE.

12 CHAIRMAN KLEIN: BECAUSE OF THE NUMBER OF
13 GRANTS THAT ARE IN EXISTENCE AND THE RECUSALS. SO
14 MR. JUELSGAARD IS NOT ON THAT LIST?

15 MR. HARRISON: WE CAN DISCUSS THAT PERHAPS
16 AT A BREAK.

17 CHAIRMAN KLEIN: OKAY. STEPHEN, I THINK
18 THAT PERHAPS, BECAUSE OF SOME OF YOUR VOLUNTEER
19 WORK, I CAN'T TAKE YOUR COMMENTS AT THIS TIME.

20 IS THERE SOMEONE WHO WOULD LIKE TO MAKE A
21 MOTION?

22 MS. SAMUELSON: I HAVE A QUESTION, BOB. I
23 HAD THOUGHT WHEN WE FIRST APPROVED THIS PROGRAM THAT
24 ESSENTIALLY THERE WOULD BE A TRAINING COMPONENT AT
25 THE FRONT END, AND THEN TRAINING WOULD HAVE BEEN

BARRISTERS' REPORTING SERVICE

1 ACCOMPLISHED. NOW, OF COURSE, I GET THAT THERE ARE
2 INDIVIDUALS WHO WOULDN'T BE INCLUDED IN THAT FOR A
3 VARIETY OF REASONS, BUT IT'S STILL A LOT OF MONEY.
4 AND SO I'M WONDERING HOW WE KNOW THAT THIS PROGRAM
5 COMPETES EFFECTIVELY WITH THE OTHER USES WE COULD
6 PUT TO THAT MONEY, WHICH THERE ARE MANY MORE THAN WE
7 HAVE MONEY TO SPEND. AND THE TRANSLATION IS OUR
8 OBJECTIVE, AND THAT THAT'S A HARD THING TO DO, AND
9 WE NEED TO BE PUTTING MORE MONEY TO THAT. CAN YOU
10 SPEAK TO THAT?

11 DR. SAMBRANO: THAT'S AN EXCELLENT
12 QUESTION. I THINK ONE OF THE THINGS THAT WE'VE
13 LEARNED THROUGH THE COURSE OF THE YEARS WITH THIS
14 PROGRAM IS THAT THE BENEFITS HAVE BEEN MORE THAN WE
15 MIGHT HAVE EXPECTED FROM JUST A TYPICAL TRAINING
16 PROGRAM. THE PUBLICATIONS ALONE DEMONSTRATE HOW
17 PRODUCTIVE TRAINEES HAVE BEEN ACROSS THE BOARD IN
18 TERMS OF DOING RESEARCH THAT SPANS FROM BASIC
19 BIOLOGY INTO TRANSLATIONAL RESEARCH.

20 THE OTHER THING, I WENT TO TWO SITE VISITS
21 YESTERDAY OF SOME OF THE PROGRAMS. AND THERE WERE
22 SOME SPECIFIC CITATIONS OF WHERE THE WORK OF
23 INDIVIDUAL TRAINEES HAS SPAWNED PROJECTS AND
24 PROPOSALS THAT HAVE LED TO APPLICATIONS THAT HAVE
25 BEEN FUNDED THROUGH THE NIH, THROUGH CIRM, AND OTHER

BARRISTERS' REPORTING SERVICE

1 FUNDING AGENCIES. SO IN MANY WAYS IT'S PROVIDING AN
2 OPPORTUNITY TO GENERATE RESEARCH THAT CAN GARNER
3 FUNDING ELSEWHERE.

4 IN ADDITION, I THINK THE PROGRAM HAS ALSO
5 BEEN CREATING A NEW WAY OF DOING THINGS AT MANY OF
6 THESE INSTITUTIONS IN PART BY BUILDING A COMMUNITY
7 OF STEM CELL SCIENTISTS. SO IT'S BEEN A GREAT
8 RECRUITING TOOL. MANY NEW SCIENTISTS AND FACULTY
9 HAVE COME TO THOSE INSTITUTIONS AS A RESULT OF THE
10 TRAINING PROGRAM BECAUSE THEY SEE THE BENEFITS OF
11 HAVING THESE TRAINEES IN THEIR OWN LABORATORIES AND
12 SEE IT AS A PLUS COMING TO CALIFORNIA.

13 THE OTHER THING, EVEN SOMETHING AS SIMPLE
14 AS THE COURSEWORK. THE STEM CELL PROGRAM OFFERS
15 KIND OF A UNIQUE PERSPECTIVE ON DOING THESE COURSES.
16 UNLIKE MOST OTHER COURSES THAT GRADUATE STUDENTS
17 TAKE, IN THIS CASE YOU HAVE PREDOCTORAL STUDENTS
18 MIXED IN WITH POST DOCS WITH CLINICAL FELLOWS, WHICH
19 IS A VERY UNIQUE SETTING. AND THAT WAS HIGHLIGHTED
20 AS A SPECIFIC BENEFIT TO THE TRAINEES TO HAVE THE
21 DIFFERENT PERSPECTIVES FROM ALL OF THESE INDIVIDUALS
22 CONTRIBUTING TO THE CLASSROOM EXPERIENCE IN A WAY
23 THAT THEY HADN'T HAD BEFORE. AND IN MANY CASES IT
24 SPAWNED COLLABORATIONS AND NEW IDEAS THAT OFTEN LEAD
25 TO MORE TRANSLATIONAL WORK.

BARRISTERS' REPORTING SERVICE

1 FOR EXAMPLE, HAVING A CLINICAL FELLOW
2 TRAINEE WITH SOME OF THESE PRE-DOCS INSPIRES A NEW
3 WAY OF THINKING THAT I THINK IS IN THE DIRECTION
4 THAT WE WANT TO GO AND PUSH THESE YOUNG SCIENTISTS
5 TOWARDS MORE TRANSLATION AND CLINICAL APPLICATIONS
6 IN THE FUTURE.

7 MS. SAMUELSON: COULD YOU GET US SOME
8 INFORMATION ABOUT THAT? BECAUSE THAT'S GIVING ME A
9 REASON TO VOTE FOR IT ESSENTIALLY BECAUSE IT'S VERY
10 IMPORTANT TO ME THAT, HOWEVER THIS TRAINING IS DONE
11 GOING FORWARD, THAT IT'S GOT AN INTENSELY
12 TRANSLATIONAL COMPONENT.

13 CHAIRMAN KLEIN: SO, JOAN, ONE OF THE
14 THINGS THAT THE SCIENTISTS IN THE LABS HAVE BEEN
15 REPORTING BACK IS THAT THIS IS RECRUITING THE BEST
16 AND THE BRIGHTEST PEOPLE FROM AROUND THE COUNTRY AND
17 FROM WITHIN CALIFORNIA INTO THE STEM CELL FIELD AT A
18 VERY HIGH LEVEL OF INITIAL PREPARATION THAT'S
19 ADVANCING THEIR RESEARCH. THE PRODUCTIVITY
20 ESSENTIALLY -- THE TOTAL NUMBER OF PAPERS WAS HOW
21 MUCH, GIL?

22 DR. SAMBRANO: IT'S 455 CURRENTLY.

23 CHAIRMAN KLEIN: IT'S MORE THAN 50 PERCENT
24 OF ALL OF THE DISCOVERIES PUBLISHED ARE COMING OUT
25 OF THESE BRILLIANT YOUNG SCIENTISTS THAT ARE IN THIS

BARRISTERS' REPORTING SERVICE

1 FELLOWSHIP PROGRAM, WHICH IS A REMARKABLE LEVEL OF
2 PRODUCTIVITY.

3 DR. TROUNSON: I THINK IT WOULD BE FAIR TO
4 SAY THAT IT'S NOT ALL CONCENTRATED ON TRANSLATION.
5 THERE'S A LOT OF BASIC RESEARCH AND TOOLS
6 DEVELOPMENTS. COVERS THE SPAN OF THE WORK WE'RE
7 DOING. THESE TRAINEES WORK TOGETHER WITH THE PI'S
8 AND THE TOP SCIENTISTS. SO, YES, IT DRAWS A LOT OF
9 THE GOOD PEOPLE INTO THE PROGRAMS, AND THEY GO INTO
10 CALIFORNIA, BUT THEY ALSO GO OTHER PLACES AS WELL
11 AND EXPAND IN THEIR DEVELOPMENT.

12 SO WE'RE ACTUALLY SEEDING A LOT OF WORK
13 BROADLY ACROSS THE SPACE, NOT SPECIFICALLY IN
14 TRANSLATION, BUT BROADLY ACROSS THE SPACE. THE
15 HEADS OF THE PROGRAMS ARE EXTREMELY SUPPORTIVE OF
16 THIS, AND THEY FIND THAT THIS IS ONE OF THE KEY
17 COMPONENTS FOR A SUCCESSFUL CENTER. AND WE'VE
18 DEVELOPED THESE CENTERS, AND THIS IS A REAL CORE
19 PART OF THEIR PROGRAM.

20 SO THEY ARE VERY SUPPORTIVE IN US
21 CONTINUING THIS AND NOT TO HAVE A BREAK IN THE
22 PROGRESS OF IT. AND SO I STRONGLY ENDORSE THIS, AND
23 I CARRY THE STRENGTH OF THE HEADS OF ALL OF THE
24 INSTITUTES IN SAYING THIS IS REALLY A PRIMARY AND
25 REALLY INTEGRATIVE AND INTEGRAL PART OF THE PROGRAMS

BARRISTERS' REPORTING SERVICE

1 THAT WE'VE ESTABLISHED.

2 CHAIRMAN KLEIN: LET ME UNDERSTAND MR.
3 HARRISON.

4 MR. HARRISON: DR. MELMED HAS A CONFLICT
5 WITH RESPECT TO THIS ISSUE.

6 DR. MELMED: I'M NOT ASKING ABOUT THE
7 ISSUE. I JUST WANTED TO CLARIFY FROM LISTENING.
8 WE'RE NOT APPROVING THE INDIVIDUALS. WE'RE
9 APPROVING THE PROGRAM ITSELF.

10 CHAIRMAN KLEIN: WE'RE APPROVING THE
11 PROGRAM ITSELF.

12 DR. MELMED: AND THE INDIVIDUALS
13 THEMSELVES ARE GOING TO UNDERGO REGULAR COMPETITION.

14 CHAIRMAN KLEIN: THAT'S A CORRECT
15 STATEMENT. THE INDIVIDUALS WHO ARE RECRUITED INTO
16 THE PROGRAM BY THEIR INSTITUTIONS FACE COMPETITION
17 WITHIN THEIR INSTITUTIONS.

18 DR. LOVE: BOB, THIS MAY BE A QUESTION
19 THAT'S BETTER FOR YOU THAN FOR GIL, ALTHOUGH GIL MAY
20 BE ALSO TO ANSWER THIS. I THINK SOME OF THE PEOPLE
21 ON THE BOARD WHO MAY NOT BE ABLE TO ASK THIS AND I
22 CAN MIGHT BE THINKING ABOUT ANY MONEY THAT WE
23 ALLOCATE GOING FORWARD ABOUT HOW THIS IMPACTS OUR
24 KIND OF CAPACITY GOING FORWARD. WE'VE HAD A LOT OF
25 KIND OF LITERATURE COMING OUR WAY TALKING ABOUT OUR

BARRISTERS' REPORTING SERVICE

1 CAPACITY TO RAISE MONEY IN THE FUTURE. AND JUST
2 PUTTING THIS INTO CONTEXT MIGHT BE USEFUL.

3 CHAIRMAN KLEIN: OBVIOUSLY A VERY
4 COMPLICATED QUESTION. THE CONTINUATION OF THIS
5 PROGRAM HAS BEEN PART OF THE STRATEGIC PLAN, AND
6 IT'S BEEN PART OF THE FINANCIAL PLAN. OUR ABILITY
7 TO CONTINUE THIS IS SIGNIFICANTLY -- COULD BE
8 SIGNIFICANTLY BETTER IF WE REACH A DECISION TODAY AS
9 VERSUS IN THE FUTURE BECAUSE IT THEN GOES INTO THE
10 FINANCIAL PLANS THE STATE LOOKS TO FUNDING. THEY'RE
11 GOING TO NEED LEAD-TIME IN BEING ABLE TO FUND THIS.

12 AND SO IT WAS SCHEDULED FOR TODAY
13 PARTICULARLY BECAUSE IT PROVIDES ENOUGH LEAD-TIME TO
14 BE ABLE TO HAVE IT TAKEN INTO ACCOUNT IN THE FUNDING
15 PLANS, BUT IT IS PART OF THE STRATEGIC PLAN THAT WAS
16 PREVIOUSLY REVIEWED. BUT I CAN'T GIVE YOU A DETAIL
17 ON IT.

18 SO LET ME ASK THIS QUESTION BECAUSE WHAT
19 WE'RE GOING TO DO IS WE'RE GOING TO LIMIT THE TIME
20 WE SPEND ON THIS ITEM, OR WE'RE GOING TO PUT IT OVER
21 TO TOMORROW MORNING. SO I WANT TO SEE DO WE HAVE
22 ANYONE WHO WANTS TO MAKE A MOTION AT THIS TIME?

23 MR. TORRES: YES. SO MOVED.

24 DR. LOVE: SECOND.

25 CHAIRMAN KLEIN: SECONDED BY DR. LOVE.

BARRISTERS' REPORTING SERVICE

1 ARE THERE COMMENTS, ADDITIONAL COMMENTS, BY THE
2 BOARD?

3 MS. SAMUELSON: I'M GOING TO VOTE FOR
4 THIS; BUT IN THE FUTURE, UNLESS IT'S CLEAR TO ME HOW
5 A GIVEN GRANT PROGRAM RELATES TO THE STRATEGIC PLAN
6 TO TRANSLATE INTO THERAPIES TO MY SATISFACTION, I
7 CAN'T. SO I JUST WANTED TO SAY THAT IN ADVANCE.
8 THANK YOU.

9 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
10 MEMBERS OF THE PUBLIC THAT WOULD LIKE TO QUICKLY
11 COMMENT. AND WE'RE GOING TO LIMIT IT TO THREE
12 MINUTES EACH. WE HAVE THREE COMMENTS.

13 MR. REED: AT THE ISSCR, WHICH IS A
14 WONDERFUL EXPERIENCE, ONE OF THE MOST HOTLY ATTENDED
15 MEETINGS WAS THE YOUNG INVESTIGATORS. AND THE ROOM
16 WAS PACKED, AND THEY WERE HANGING ON EVERY WORD.
17 THE NEED FOR THIS GRANT IS CRUCIAL. THANK YOU.

18 DR. CHIU: I JUST WANT TO MAKE THREE
19 POINTS.

20 CHAIRMAN KLEIN: YOU WANT TO JUST
21 ANNOUNCE.

22 DR. CHIU: THIS IS ARLENE CHIU FROM THE
23 CITY OF HOPE. AND I'D LIKE TO MAKE THREE POINTS IN
24 COMPARING THIS PROGRAM WITH ANYTHING LIKE IT AT THE
25 NIH.

BARRISTERS' REPORTING SERVICE

1 NO. 1, THE NIH ISSUES TRAINING GRANTS
2 USUALLY FOCUSED ON A DISEASE OR AN ORGAN SYSTEM,
3 NEVER ON STEM CELL PROGRAMS UNLESS IT'S JUST FOR
4 TECHNIQUES. SO THIS IS VERY UNIQUE BECAUSE IT
5 ALLOWS LABS TO HIRE POST DOCS AND FELLOWS TO COME TO
6 THE LAB TO WORK ON A STEM CELL PROGRAM.

7 NO. 2, NIH PROGRAMS LIKE THIS REQUIRE
8 PERMANENT RESIDENCY OR CITIZENSHIP, WHICH MAY NOT BE
9 THE BRIGHTEST OR THE BEST POST DOCS AND FELLOWS THAT
10 WE HAVE. THIS PROGRAM ALLOWS ANYBODY WHO'S GOOD
11 ENOUGH TO BE SELECTED SO THAT THEY CAN CONTINUE ON
12 TO DO GREAT STEM CELL RESEARCH.

13 AND THE THIRD IS NOWHERE IN ANY STATE HAS
14 THERE BEEN SO MANY OF THESE PROGRAMS. SO YOU'RE
15 REALLY GROWING THE NEXT GENERATION OF STEM CELL
16 SCIENTISTS. AND I THINK BASED ON WHAT DR. SAMBRANO
17 HAS SAID, THIS IS EXTRAORDINARILY SUCCESSFUL. SO
18 THANK YOU.

19 CHAIRMAN KLEIN: THANK YOU. DR. CHIU WAS
20 THE DIRECTOR, ORIGINAL, FIRST DIRECTOR, SCIENTIFIC
21 OFFICER FOR THE AGENCY, MADE AN INCREDIBLE
22 CONTRIBUTION. SO THANK YOU, DR. CHIU. DR. LORING.

23 DR. LORING: I THINK I'M PREACHING TO THE
24 CHOIR, SO I'LL BE REALLY BRIEF. AS A RESEARCH
25 SCIENTIST WHO'S A MENTOR TO SOME OF THESE FELLOWS, I

BARRISTERS' REPORTING SERVICE

1 SEE THESE PEOPLE AS THE WAVE OF THE FUTURE. IN A
2 FEW YEARS I'LL BE RETIRING, AND THESE OTHER PEOPLE
3 ARE GOING TO GO ON AND CARRY ON STEM CELL RESEARCH
4 ALL OVER THE WORLD.

5 POST DOCS WORK SOMETIMES 24 HOURS A DAY.
6 THESE ARE THE SOLDIERS IN THE RESEARCH FIGHT. IF
7 THEY WEREN'T FUNDED, I COULDN'T GET ANYTHING DONE.
8 SO I URGE YOU TO VOTE FOR THIS AND SUPPORT THE
9 PEOPLE WHO ARE ACTUALLY DOING THE WORK.

10 CHAIRMAN KLEIN: THANK YOU VERY MUCH. SO
11 I'D LIKE TO CALL THE QUESTION, IF WE COULD. BECAUSE
12 OF THE CONFLICTS, I THINK WE'RE GOING TO DO A ROLL
13 CALL; IS THAT CORRECT? YES.

14 WOULD COUNSEL STATE THE MOTION?

15 MR. HARRISON: THE MOTION IS TO APPROVE
16 THE EXTENSION OF THE TRAINING GRANT II PROGRAM.

17 MS. KING: I WILL ONLY CALL THE NAMES OF
18 THOSE MEMBERS WHO ARE ELIGIBLE TO VOTE ON THIS ITEM.

19 BOB KLEIN. YES.

20 MS. KING: TED LOVE.

21 DR. LOVE: YES.

22 MS. KING: ROBERT QUINT.

23 DR. QUINT: YES.

24 MS. KING: JOAN SAMUELSON.

25 MS. SAMUELSON: YES.

BARRISTERS' REPORTING SERVICE

1 MS. KING: DAVID SERRANO-SEWELL HAS
2 STEPPED OUT. JON SHESTACK.

3 MR. SHESTACK: YES.

4 MS. KING: ART TORRES.

5 MR. TORRES: AYE.

6 MR. HARRISON: THE MOTION PASSES.

7 CHAIRMAN KLEIN: THANK YOU. I'M GOING TO
8 QUICKLY GO TO ITEM 16 AND MAKE CERTAIN THAT WE CAN
9 DEAL WITH THIS ITEM QUICKLY.

10 DR. YAFFE, IF YOU WILL MAKE A SHORT
11 PRESENTATION. WE HAVE A TREMENDOUS AMOUNT OF
12 POSITIVE FEEDBACK. THIS IS BRIDGES TO STEM CELL
13 AWARDS. IT IS INVOLVING BOTH THE STATE COLLEGE
14 SYSTEM AND THE COMMUNITY COLLEGE. AS WE KNOW,
15 BAYBIO AMONG OTHERS OUTLINED THE FACT THAT WE'RE
16 GOING TO FACE A TREMENDOUS SHORTAGE OF PEOPLE WITH
17 THE TECHNICAL TRAINING TO REALLY DRIVE THIS RESEARCH
18 FORWARD AT EACH STAGE IN ADDITION TO THE FACT THAT
19 WE LACK AN EQUITABLE GATEWAY FOR PEOPLE WITH GREAT
20 ABILITY WHO MAY NOT BE IN THE GREAT UNIVERSITIES TO
21 GO INTO MASTER'S AND DOCTORAL PROGRAMS AND PURSUE
22 THEIR PASSION FOR STEM CELL RESEARCH.

23 SO THIS HAS A COUPLE OF MAJOR
24 CONTRIBUTIONS TO THAT PROCESS. DR. YAFFE.

25 DR. YAFFE: THANK YOU. MR. CHAIRMAN,

BARRISTERS' REPORTING SERVICE

1 MEMBERS OF THE BOARD, MEMBERS OF THE PUBLIC, I BRING
2 FOR YOUR CONSIDERATION A PROPOSAL FOR AN EXTENSION
3 OF THE BRIDGES TO STEM CELL RESEARCH AWARDS. THIS
4 IS ITEM NO. 16.

5 I'LL JUST REMIND YOU, AS I THINK MANY OF
6 YOU ARE FAMILIAR WITH THE PROGRAM, THAT THE GOALS OF
7 THIS PROGRAM ARE TO EXPAND CALIFORNIA'S WORKFORCE IN
8 STEM CELL SCIENCE AND REGENERATIVE MEDICINE, AND TO
9 PROVIDE RESEARCH OPPORTUNITIES FOR STUDENTS
10 REPRESENTING THE DIVERSITY OF CALIFORNIA'S
11 POPULATION, AND PARTICULARLY FOR STUDENTS, AS
12 CHAIRMAN KLEIN HAS SAID, AT STATE UNIVERSITIES AND
13 COMMUNITY COLLEGES.

14 THE PROGRAM FEATURES RESEARCH INTERNSHIPS
15 AT STEM CELL LABS, TECHNIQUES COURSES AT CIRM-FUNDED
16 SHARED LAB OR EQUIVALENT FACILITIES, INTEGRATION OF
17 INTERNSHIPS WITH UNDERGRADUATE OR MASTER'S LEVEL
18 PROGRAMS AT HOME INSTITUTIONS, AND SUPPORTIVE AND
19 COMPLEMENTARY EDUCATIONAL ACTIVITIES INCLUDING
20 SPECIALIZED COURSES AND SEMINARS.

21 EACH AWARD SUPPORTS UP TO TEN INTERN
22 TRAINEES WHO ARE UNDERGRADUATE OR MASTER'S LEVEL
23 STUDENTS PER YEAR FOR INTERNSHIPS OF SIX TO TWELVE
24 MONTHS DURATION. CIRM FUNDED 16 OF THESE PROGRAMS
25 FOR A TERM OF THREE YEARS. THE EARLIEST PROGRAMS

BARRISTERS' REPORTING SERVICE

1 BEGAN IN THE FALL OF 2009, AND SOME OF THE PROGRAMS
2 BEGAN LATER IN THAT ACADEMIC YEAR.

3 THE OVERALL PROGRAM COST WHICH YOU
4 APPROVED PREVIOUSLY WAS \$24 MILLION. THIS MAP SHOWS
5 THE DISTRIBUTION OF BRIDGES PROGRAMS. THE
6 INSTITUTIONS WHICH SERVE AS HOME INSTITUTIONS,
7 THEY'RE SPREAD THROUGHOUT THE STATE OF CALIFORNIA
8 FROM HUMBOLDT IN THE NORTH TO HERE IN SAN DIEGO.
9 ADDITIONALLY, THE SMALL RED TRIANGLES, IF YOU CAN
10 SEE THEM -- I CAN SEE THEM HERE, BUT I'M NOT SURE
11 YOU CAN SEE THEM THERE -- REPRESENT THE INTERNSHIP
12 HOST INSTITUTIONS. THESE ARE 23 RESEARCH
13 UNIVERSITIES AND INSTITUTES AND EIGHT BIOTECH
14 COMPANIES WHICH SERVE AS THE SITES FOR THE RESEARCH
15 INTERNSHIPS OF THE TRAINEES.

16 THESE BRIDGES PROGRAMS ARE CLOSELY
17 MONITORED BY CIRM STAFF, AND THIS MONITORING
18 INCLUDES CIRM APPROVAL OF TRAINEE APPOINTMENTS AND
19 INTERNSHIP ASSIGNMENTS, AN ANNUAL PROGRESS REPORT
20 PREPARED BY THE PROGRAM DIRECTORS AND REVIEWED BY
21 OUR GRANTS MANAGEMENT STAFF AND CIRM SCIENCE
22 OFFICERS, AS WELL AS AN ANNUAL BRIDGES TRAINING
23 MEETING IN WHICH WE HAVE AN OPPORTUNITY TO TALK WITH
24 THE TRAINEES THEMSELVES, HEAR ABOUT THEIR
25 ACTIVITIES, THEIR EXPERIENCE IN THE PROGRAM, AND,

BARRISTERS' REPORTING SERVICE

1 MOST IMPORTANTLY, ABOUT THEIR RESEARCH
2 ACCOMPLISHMENTS.

3 WHILE THIS PROGRAM HAS ONLY BEEN RUNNING
4 FOR BETWEEN ONE AND TWO YEARS, DEPENDING ON THE
5 PROGRAM, THERE'S ALREADY WHAT I THINK IS SPECTACULAR
6 SUCCESS. INTERNSHIP MENTORS AND FACULTY AT THE
7 RESEARCH UNIVERSITIES REPORT OUTSTANDING QUALITY,
8 DEDICATION, ENTHUSIASM, AND PERFORMANCE OF THESE
9 TRAINEES. PROGRAM DIRECTORS CITE GROWING INTEREST
10 IN THE PROGRAMS BY PROSPECTIVE TRAINEES AS WELL AS
11 INTEREST IN THE GRADUATES OF THESE PROGRAMS BY
12 DIRECTORS OF LABORATORIES BOTH AT COMPANIES AND AT
13 RESEARCH INSTITUTES.

14 A RECENT SURVEY OF THE CURRENT ACTIVITY OF
15 163 FORMER TRAINEES REVEALED THAT 52 PERCENT
16 OBTAINED LAB JOBS, MOST OF THESE IN CALIFORNIA, MANY
17 IN THE LABS IN WHICH THE TRAINEES CARRIED OUT THEIR
18 INTERNSHIPS. 26 PERCENT ACCEPTED OR ARE ENROLLED IN
19 GRADUATE OR PROFESSIONAL PROGRAMS, MAINLY M.D. AND
20 PH.D. PROGRAMS. OTHERS ARE STILL IN THEIR CURRENT
21 MATRICULATION IN BACHELOR'S OR MASTER'S PROGRAMS.
22 THEY'VE OBTAINED TEACHING JOBS, OR THEY'RE IN THE
23 PROCESS OF APPLYING FOR GRADUATE OR PROFESSIONAL
24 SCHOOLS.

25 OUR PROPOSAL IS TO EXTEND CIRM SUPPORT FOR

BARRISTERS' REPORTING SERVICE

1 THE BRIDGES TO STEM CELL RESEARCH AWARDS FOR AN
2 ADDITIONAL THREE YEARS BEYOND THE INITIAL THREE-YEAR
3 PERIOD. WE WILL EXTEND FUNDING FOR CURRENT PROGRAMS
4 THAT ARE IN GOOD STANDING AND DEMONSTRATE EFFECTIVE
5 PROGRAM PERFORMANCE. OUR CURRENT ASSESSMENT IS THAT
6 ALL 16 PROGRAMS ARE IN GOOD STANDING. WE ALSO
7 MAINTAIN CURRENT FUNDING LEVELS EXCEPT FOR INCREASES
8 TO COVER HIGHER STUDENT TUITION COSTS. TOTAL
9 REQUESTED IS \$26.7 MILLION.

10 CHAIRMAN KLEIN: THANK YOU, DR. YAFFE.

11 DR. SUSAN BAXTER, VICE CHANCELLOR FOR THE
12 STATE UNIVERSITY PROGRAM, WHO HAS BEEN A CRITICAL
13 FORCE IN DRIVING THIS PROGRAM FORWARD, IS PRESENT
14 ALONG WITH THE PROGRAM DIRECTOR AND TWO STUDENTS.
15 DR. BAXTER, WOULD YOU LIKE TO MAKE A SHORT STATEMENT
16 OF THREE MINUTES?

17 DR. BAXTER: I APPRECIATE THE PROMOTION,
18 BUT I'M AN EXECUTIVE DIRECTOR STILL, NOT ASSISTANT
19 VICE CHANCELLOR.

20 CHAIRMAN KLEIN: WE HAVE HIGH HOPES FOR
21 YOU.

22 DR. BAXTER: I THINK THAT I'M HERE REALLY
23 ON BEHALF OF THE CSU OFFICE OF THE CHANCELLOR TODAY
24 TO ENCOURAGE YOU TO GO AHEAD AND CONSIDER FUNDING
25 MORE OF THESE PROGRAMS AND CONTINUING THE PROGRAMS

BARRISTERS' REPORTING SERVICE

1 THAT ARE ALREADY IN PLACE.

2 THE CSU AND OUR CCC PARTNERS, ONE OF WHOM
3 IS WITH US TODAY, SUPPORT THIS PROGRAM STRONGLY AND
4 WILL CONTINUE TO PROVIDE INSTITUTIONAL AND
5 INFRASTRUCTURE SUPPORT AND COMMITMENT BECAUSE IT
6 PROVIDES RESOURCES DIRECTLY TO THE STUDENTS SINCE
7 IT'S A NETWORK OF INSTITUTIONS WORKING ON THIS
8 PROGRAM.

9 OF COURSE, WE THANK THE OUTGOING CHAIR AND
10 THE ICOC FOR INCLUDING THE BRIDGES PROGRAM IN YOUR
11 STRATEGIC VISION OF CIRM AND THE SERVICE TO
12 CALIFORNIA.

13 WE ALSO HAVE BEEN MONITORING THIS PROGRAM
14 FROM OUR END OF THE CSU. TO DATE THE BRIDGES
15 PROGRAM HAS DIRECTLY IMPACTED THE CAREERS OF OVER
16 300 CSU STUDENTS, HAS LED TO 26 NEW COURSES THAT
17 HAVE ENROLLED OVER 2200 STUDENTS. IT'S SPARKED
18 CURIOSITY AND INTEREST ACROSS THE STATE IN STEM CELL
19 BIOLOGY AND TECHNOLOGIES.

20 NICOLE BORNEUS (PHONETIC), WHO COULD NOT
21 BE HERE THIS EVENING, IS THE PI AT CSU SAN
22 BERNARDINO. SHE WROTE, "THE INLAND EMPIRE IS
23 EXPERIENCING RECORD LEVELS OF UNEMPLOYMENT. AND
24 THIS PROGRAM IS CERTAINLY A RAY OF SUNSHINE. ALL
25 SIX OF OUR INITIAL STUDENTS ARE DOING EXCELLENT JOBS

BARRISTERS' REPORTING SERVICE

1 IN THEIR RESEARCH POSTS AND JUST PRESENTED THEIR
2 WORK TO THE BIOLOGY DEPARTMENT FACULTY AND STUDENTS.
3 I COULD SEE LOTS OF EXCITEMENT AND INTEREST IN THE
4 ROOM. I FEEL I AM NOW TRULY MENTORING AND ENABLING
5 STUDENTS IN OUR REGION TO FIGURE OUT A PATHWAY TO A
6 SUCCESSFUL CAREER OR FURTHER STUDY."

7 IN TURN, WE ALSO KNOW FROM THE COMMENTS
8 WE'RE HEARING THAT THE PLACEMENTS OF CSU AND CCC
9 STUDENTS IN RESEARCH LABORATORIES ACROSS THE STATE
10 HAS INCREASED AWARENESS OF AND APPRECIATION FOR THE
11 COMPETENCE AND CONTRIBUTIONS OF OUR STUDENTS.

12 WE'VE BEEN CURIOUS TO KNOW DO THE BRIDGES
13 INTERNS COMPLETE THEIR DEGREE PROGRAMS. WE'RE VERY
14 CONCERNED ABOUT GRADUATION RATES IN THE CSU. AND WE
15 ALSO WANT TO KNOW WHETHER THEY'RE FINDING EMPLOYMENT
16 OR ENTERING GRADUATE SCHOOL AS A RESULT OF THE
17 PROGRAM. AS MICHAEL HAS ALREADY INDICATED, THE
18 ANSWERS ARE ALL A RESOUNDING YES.

19 OUR INFORMAL SURVEY OF THE STUDENTS WHO
20 HAVE COMPLETED BOTH THEIR DEGREE PROGRAMS AND THE
21 BRIDGES INTERNSHIPS THEMSELVES SHOW THAT ROUGHLY 82
22 PERCENT OF THE BRIDGES INTERNS HAVE LANDED JOBS OR A
23 PLACE IN GRADUATE SCHOOLS. SO OUR NUMBERS ARE
24 SLIGHTLY HIGHER JUST LOOKING AT THAT FIRST COHORT OF
25 STUDENTS. FOR COMPARISON, THE *NEW YORK TIMES*

BARRISTERS' REPORTING SERVICE

1 REPORTED MAY 19TH THAT ONLY 56 PERCENT OF 2010
2 COLLEGE GRADUATES FOUND JOBS THAT REQUIRED A COLLEGE
3 DEGREE. SO WE ARE CLEAR THAT OUR BRIDGES GRADUATES
4 ARE LANDING RELEVANT DEGREE REQUIRING JOBS, AND
5 THEY'RE FINDING THEM IN STEM CELL FIELDS.

6 WE'RE ALSO CURIOUS ABOUT WHETHER OR NOT
7 THE INTERNS WERE MEETING MENTOR'S EXPECTATIONS. IN
8 OTHER WORDS, AFTER THE COURSEWORK AT THE CSU, ARE
9 THEY PREPARED FOR RESEARCH POSITIONS? ONE WAY TO
10 LOOK AT THIS IS ALREADY, AS MICHAEL INDICATED, HOW
11 EAGER ARE THE HOSTS TO TAKE THEM BACK AFTER THEY'VE
12 HOSTED ONE STUDENT? THE INTERN SLOTS AVAILABLE HAS
13 GROWN YEAR ON YEAR EVERY YEAR.

14 ACCORDING TO THE INTERNSHIP MENTORS
15 ASSESSED FROM CSU FULLERTON, THEY DID A FORMAL
16 ASSESSMENT, FIVE OF THE TEN FULLERTON UNDERGRADS
17 WERE CONSIDERED TO BE COMPARABLE TO FIRST YEAR PH.D.
18 STUDENTS FOR THEIR ABILITY TO PERFORM RESEARCH, AND
19 TWO OF THE FULLERTON UNDERGRADS WERE CONSIDERED TO
20 BE ABOVE EXPECTATIONS WHEN COMPARING TO FIRST-YEAR
21 PH.D. STUDENTS. AND ANECDOTALLY, DR. IRVING
22 WEISSMAN WROTE TO JACOB VARKEY, STATING THAT
23 HUMBOLDT STATE INTERNS ARE PRACTICALLY STANFORD
24 GRADUATE STUDENTS.

25 ANOTHER WAY TO ASSESS RESEARCH READINESS

BARRISTERS' REPORTING SERVICE

1 OF THE INTERNS, OF COURSE, IS TO LOOK AT GRADUATE
2 SCHOOL ACCEPTANCE RATES. OUR NUMBERS INDICATE 34 OF
3 THE GRADUATING OR THE FIRST COHORT OF STUDENTS HAVE
4 GONE ON TO GRADUATE SCHOOL. THEY'VE ENTERED
5 DOCTORAL AND MEDICAL SCHOOL PROGRAMS AT BERKELEY,
6 DAVIS, IRVINE, SANTA BARBARA, SANTA CRUZ, UNIVERSITY
7 OF OREGON, OREGON STATE, UNIVERSITY OF COLORADO,
8 WASHINGTON, WASHINGTON STATE, UNIVERSITY OF CHICAGO,
9 UNIVERSITY OF PENNSYLVANIA, AND UNIVERSITY OF MIAMI.
10 SO THEY'RE DOING VERY WELL.

11 CHAIRMAN KLEIN: THANK YOU. WOULD YOUR
12 PROGRAM DIRECTOR LIKE TO JUST MAKE A VERY SHORT
13 STATEMENT? OKAY. THIS IS BIANCA MOTHE FROM CSU SAN
14 MARCOS.

15 MS. MOTHE: SO I WANTED TO TAKE THIS
16 OPPORTUNITY TO GIVE A LITTLE UPDATE ON OUR PROGRAM.
17 SO WE ARE CAL STATE SAN MARCOS. WE'RE IN NORTH
18 COUNTY SAN DIEGO. AND OUR PROGRAM HAS PARTNERED UP
19 WITH TWO COMMUNITY COLLEGES, MIRACOSTA AND MIRAMAR
20 HERE IN SAN DIEGO COUNTY.

21 CURRENTLY WE HAVE THREE BRIDGES INTERNS --
22 30 BRIDGES INTERNS AT SOME STAGE OF DEVELOPMENT.
23 TEN THAT HAVE COMPLETED THE PROGRAM. AND OF THOSE
24 TEN, THREE OF THEM HAVE ENTERED ADVANCED EDUCATION.
25 SO TWO OF THEM ARE IN PH.D. PROGRAMS RIGHT NOW, ONE

BARRISTERS' REPORTING SERVICE

1 AT THE UNIVERSITY OF PENNSYLVANIA, HHMI REGENERATIVE
2 MEDICINE SUPPORTED PROGRAM. ANOTHER ONE IS GOING TO
3 BE STARTING THE UC RIVERSIDE REGENERATIVE MEDICINE
4 PROGRAM IN THE FALL. AND ONE IS IN A MASTER'S
5 PROGRAM AT CAL STATE SAN MARCOS.

6 OUT OF THE OTHER STUDENTS, FIVE OF THEM
7 HAVE CONTINUED AS TECHNICAL RESEARCH ASSISTANTS OR
8 TECHNICIANS IN STEM CELL RESEARCH, AND TWO OF THEM
9 ARE CURRENTLY COMPLETING THEIR DEGREES, BUT ARE
10 WORKING PART TIME IN THE LABS WHERE THEY DID THEIR
11 INTERNSHIPS. SO WE'RE EXPECTING THEM TO CONTINUE AS
12 WELL.

13 WE ALSO HAVE A GENERAL EDUCATION COURSE,
14 WHICH HAS PROBABLY BEEN ONE OF THE HIGHLIGHTS OF OUR
15 PROGRAM. IT'S CALLED "TRENDS IN 21ST CENTURY
16 MEDICINE." AND THAT COURSE HAS BEEN OFFERED THREE
17 TIMES PER YEAR ON OUR CAMPUS IN A SITUATION WHERE
18 THAT COURSE PROBABLY OTHERWISE WOULD NOT HAVE BEEN
19 OFFERED IF IT WEREN'T SUPPORTED BY THIS PROGRAM.
20 AND THAT COURSE HAS REACHED OUT TO 300 NON-LIFE
21 SCIENCE MAJOR STUDENTS.

22 LASTLY, WE'VE LAUNCHED A SEMINAR SERIES ON
23 OUR CAMPUS, ALSO SUPPORTED BY THIS PROGRAM, AND
24 WE'VE BEEN ABLE TO BRING IN EIGHT SPEAKERS FROM THE
25 REGION. AND THAT SEMINAR SERIES IS OPEN TO THE

BARRISTERS' REPORTING SERVICE

1 COMMUNITY AND TO FACULTY, STAFF, AND STUDENTS ON OUR
2 CAMPUS. SO I THINK WITH THIS PROGRAM, WE'VE REALLY
3 BEEN ABLE TO REACH A COHORT OF PEOPLE THAT NEVER
4 WOULD HAVE BEEN EXPOSED TO STEM CELL RESEARCH IN THE
5 FIRST PLACE.

6 CHAIRMAN KLEIN: THANK YOU VERY MUCH.

7 MS. MOTHE: AND I HAVE TWO STUDENTS FROM
8 OUR FIRST COHORT.

9 CHAIRMAN KLEIN: I'M GOING TO ASK SENATOR
10 TORRES TO MAKE A STATEMENT THAT HE'D LIKE TO MAKE.
11 AND THEN IF THE TWO STUDENTS, WHILE HE'S MAKING THE
12 STATEMENTS, COME UP TO THE MIC JUST SO WE CAN
13 RECOGNIZE YOU.

14 MR. TORRES: IF WE COULD PUT THE MAP BACK
15 ON ON THE BRIDGES PROGRAM. MR. CHAIRMAN AND
16 MEMBERS, MY NEW ASSISTANT DOUG GUIONE, WHO USED TO
17 BE THE OFFICE MANAGER FOR CIRM, HELPED ME SEND
18 LETTERS TO EVERY MEMBER OF CONGRESS, EVERY MEMBER OF
19 THE LEGISLATURE, BOTH ASSEMBLY AND SENATE, IN WHICH
20 ALL OF THESE PROJECTS THAT WE HAVE FUNDED ARE IN
21 THEIR DISTRICTS. IT'S IMPORTANT FOR US TO CONTINUE
22 TO COMMUNICATE TO POLICYMAKERS AT THE FEDERAL AND
23 STATE LEVEL AS TO WHAT'S GOING ON IN THEIR BACKYARD
24 WITH TAXPAYER DOLLARS THAT HAVE BEEN APPROVED AND
25 APPROVED BY THIS BOARD.

BARRISTERS' REPORTING SERVICE

1 THE RESPONSE THAT I RECEIVED INITIALLY
2 FROM THESE LETTERS, WHICH JUST WENT OUT A FEW WEEKS
3 AGO, HAS BEEN PHENOMENAL. PEOPLE ARE CONCERNED
4 ABOUT THE FUTURE OF THIS STATE, AND THERE'S NO
5 BETTER PROGRAM THAT WE CAN ATTACH AND SUPPORT THAN
6 THIS BRIDGES PROGRAM, WHICH REACHES OUT INTO NOT
7 JUST THE STANFORDS AND THE UCLAS AND THE USCS AND
8 THE UC BERKELEYS, BUT REACHES OUT TO THE STATE
9 UNIVERSITY SYSTEM, THE COMMUNITY COLLEGE SYSTEM
10 BECAUSE YOUNG SCIENTISTS WHO ARE PROMISING ARE
11 EVERYWHERE.

12 CHAIRMAN KLEIN: THANK YOU VERY MUCH.
13 SHERRY LANSING.

14 MS. LANSING: SINCE THIS IS ONE OF FEW THE
15 THINGS THAT I'M NOT CONFLICTED ON, I WOULD LIKE
16 TO --

17 MR. HARRISON: YOU ACTUALLY ARE.

18 MS. LANSING: I AM? HOW? WHY?

19 CHAIRMAN KLEIN: I'D LIKE TO POINT TO
20 THOSE LISTENING THAT SHERRY HAS JUST BEEN ELECTED AS
21 THE CHAIR OF THE BOARD OF REGENTS OF THE UNIVERSITY
22 OF CALIFORNIA SYSTEM.

23 (APPLAUSE.)

24 MS. LANSING: ALL I WANT TO DO IS
25 ENTHUSIASTICALLY ENDORSE THIS.

BARRISTERS' REPORTING SERVICE

1 MR. TORRES: WELL, YOU DID THROUGH ME.

2 CHAIRMAN KLEIN: SO DAVID SERRANO-SEWELL,
3 THIS IS A TASK FORCE THAT YOU AND MARCY FEIT LED
4 THAT HAS PRODUCED THIS GREAT PROGRAM. WOULD YOU
5 LIKE TO MAKE ANY STATEMENT OR A MOTION?

6 MR. SERRANO-SEWELL: I WOULD MOVE FOR
7 APPROVAL FOR FUNDING.

8 CHAIRMAN KLEIN: IS THERE A SECOND?

9 MR. SHESTACK: SECOND.

10 CHAIRMAN KLEIN: SECOND BY JONATHAN
11 SHESTACK. COULD WE QUICKLY RECOGNIZE THE TWO
12 STUDENTS AND JUST TELL US WHAT INSTITUTION YOU'RE
13 WITH.

14 MS. MOTHE: I'LL JUST INTRODUCE BRIEFLY.
15 WE HAVE CARRIE COX AND VICTORIA GLENN WHO BOTH WERE
16 IN THE FIRST COHORT OF OUR PROGRAM AT CAL STATE SAN
17 MARCOS.

18 (APPLAUSE.)

19 CHAIRMAN KLEIN: JUST TAKE ONE MINUTE. GO
20 AHEAD, EACH OF YOU.

21 MS. COX: MY NAME IS CARRIE COX, AND I
22 JUST WANT TO SAY THANK YOU FOR GIVING US THE
23 OPPORTUNITY TO SPEAK HERE TODAY, AND I APPRECIATE
24 THE UNIQUE OPPORTUNITY TO PARTICIPATE IN THE BRIDGES
25 PROGRAM.

BARRISTERS' REPORTING SERVICE

1 MY INTERNSHIP WAS WITH MARCUS KAUL AT THE
2 SANFORD-BURNHAM INSTITUTE IN SAN DIEGO. AND I THINK
3 THE CRUCIAL POINTS HERE IS THAT THE BRIDGES PROGRAM
4 EMPOWERED ME TO BE ABLE TO DO FULL-TIME RESEARCH
5 WHILE ATTENDING SCHOOL WITH THE FINANCIAL BACKING
6 SINCE I DID PUT MYSELF THROUGH SCHOOL, ALSO THE
7 SKILL SET TO PURSUE A CAREER IN RESEARCH AND
8 CLARIFIED FUTURE DIRECTION FOR ME. I'M CURRENTLY
9 APPLYING TO GRADUATE PROGRAMS. SO THANK YOU VERY
10 MUCH.

11 (APPLAUSE.)

12 MS. GLENN: MY NAME IS VICTORIA GLENN. I
13 WAS ALSO WITH CARRIE COX IN THE FIRST COHORT FROM
14 CAL STATE SAN MARCOS. I COMPLETED MY YEAR WITH
15 ACTUALLY DR. JEANNE LORING HERE IN GENERATING A BANK
16 OF ETHNICALLY DIVERSE PLURIPOTENT STEM CELLS, A
17 PROJECT WHICH I'M PROUD TO SAY THAT I'VE BEEN ABLE
18 TO HELP CONTINUE AS A MASTER'S STUDENT AT CAL STATE
19 SAN MARCOS. I'M ALSO APPLYING TO GRADUATE PROGRAMS
20 AS WELL, HOPING TO CONTINUE IN STEM CELL RESEARCH.
21 SO THANK YOU AGAIN SO MUCH FOR THIS OPPORTUNITY.

22 (APPLAUSE.)

23 CHAIRMAN KLEIN: WE HAVE A MOTION AND A
24 SECOND. I'D CALL THE QUESTION. MELISSA, COULD YOU
25 PLEASE READ THE ROLL.

BARRISTERS' REPORTING SERVICE

1 MS. KING: AGAIN, I WILL CALL THE NAMES OF
2 ONLY THOSE MEMBERS ELIGIBLE TO VOTE ON THIS ITEM.

3 BOB KLEIN.

4 CHAIRMAN KLEIN: YES.

5 MS. KING: TED LOVE.

6 DR. LOVE: YES.

7 MS. KING: ROBERT QUINT.

8 DR. QUINT: YES.

9 MS. KING: JOAN SAMUELSON.

10 MS. SAMUELSON: YES.

11 MS. KING: DAVID SERRANO-SEWELL.

12 MR. SERRANO-SEWELL: YES.

13 MS. KING: JON SHESTACK.

14 MR. SHESTACK: YES.

15 MS. KING: ART TORRES.

16 MR. TORRES: AYE.

17 I CAN SAY COMFORTABLY THAT MOTION CARRIES.

18 CHAIRMAN KLEIN: SO, MR. HARRISON, SINCE
19 THE VOTE'S ALREADY BEEN TAKEN, I THINK I COULD ASK
20 SHERRY LANSING FOR HER STATEMENT.

21 MS. LANSING: I WANT TO SAY AS CHAIR OF
22 THE REGENTS AND AS A MEMBER OF THE STEM CELL BOARD
23 HOW ENTHUSIASTICALLY I ENDORSE THIS PROPOSAL. I'M
24 ALLOWED TO SAY THAT, RIGHT, AND HOW VITAL I THINK
25 THE CAL STATE SYSTEM IS TO ALL THE CITIZENS OF

BARRISTERS' REPORTING SERVICE

1 CALIFORNIA AND HOW PROUD I AM THAT WE'RE DOING THIS.

2 CHAIRMAN KLEIN: SO WITH THAT ACTION,
3 WE'RE NOW GOING TO GO DIRECTLY TO THE CHAIR
4 SELECTION PROCESS.

5 COUNSEL, MY UNDERSTANDING OF OUR SEQUENCE
6 HERE, TO STAY WITH OUR PROCESS, IS THAT WE ARE GOING
7 TO HAVE EACH OF THE CANDIDATES MAKE A PUBLIC
8 STATEMENT, THEN WE ARE GOING TO GO TO EXECUTIVE
9 SESSION. WE CAN TAKE -- I'D LIKE TO SEE HOW MANY
10 PUBLIC COMMENTS THERE ARE BEFORE WE GO TO EXECUTIVE
11 SESSION TO SEE IF WE CAN ACCOMMODATE THEM BEFORE
12 EXECUTIVE SESSION.

13 MR. HARRISON: YES. THE PLAN WAS TO HAVE
14 THE PUBLIC PRESENTATIONS FIRST, PUBLIC COMMENT, AND
15 THEN EXECUTIVE SESSION. THE ACCOUNTING FIRM OF
16 MELISSA KING AND HARRISON FLIPPED A COIN TO
17 DETERMINE WHO WOULD GO FIRST, AND FRANK LITVACK WON
18 THAT HONOR.

19 CHAIRMAN KLEIN: DR. LITVACK, IF YOU COULD
20 MAKE THE FIRST PRESENTATION.

21 AND I WOULD LIKE TO SAY THAT THIS BOARD IS
22 EXTREMELY PRIVILEGED TO HAVE THESE TWO CANDIDATES.
23 THEY BOTH BRING REMARKABLE HISTORIES, EXTRAORDINARY
24 TALENTS TO THIS. IT IS A TREMENDOUS OPPORTUNITY FOR
25 THIS BOARD TO CHOOSE BETWEEN DIFFERENT AREAS OF

BARRISTERS' REPORTING SERVICE

1 EXPERTISE.

2 AND I WOULD LIKE REALLY TO COMPLIMENT THE
3 BOARD. HAVING SAT AT THE CHAIR FOR SIX AND A HALF
4 YEARS AND HAVING HAD PERSONAL CONVERSATIONS WITH
5 BOTH DR. LITVACK AND JON THOMAS ABOUT THE TREMENDOUS
6 EFFORT AND THE INTENSITY OF THE EFFORT OF THIS
7 POSITION, IT IS A VERY GREAT PRIVILEGE TO HAVE THEM
8 BE WILLING TO MAKE THE PUBLIC SERVICE SACRIFICE TO
9 STAND FOR ELECTION FOR THIS BOARD AND SERVE IF
10 ELECTED. SO WE'RE VERY GRATEFUL.

11 AND, DR. LITVACK, IF YOU COULD SPEAK
12 FIRST.

13 DR. LITVACK: THANK YOU SO MUCH, BOB.
14 GOOD AFTERNOON, EVERYBODY, MEMBERS OF THE ICOC AND
15 MEMBERS OF THE PUBLIC WHO ARE HERE AND LISTENING IN.
16 THANK YOU FOR YOUR TIME AND ATTENTION.

17 ALLOW ME TO BEGIN BY RECOGNIZING THE
18 OUTSTANDING CONTRIBUTIONS AND THE DEDICATION OF THE
19 MANY TALENTED PEOPLE WHO SERVE ON THE ICOC BOARD AS
20 WELL AS, OF COURSE, MEMBERS OF THE CIRM STAFF.

21 AS HE NOW STEPS DOWN FROM THE CHAIR,
22 CONGRATULATIONS AND THANKS ARE IN ORDER TO BOB KLEIN
23 FOR A JOB EXTRAORDINARILY WELL DONE.

24 I ALSO CONGRATULATE JON THOMAS FOR HIS
25 NOMINATION.

BARRISTERS' REPORTING SERVICE

1 ALLOW ME TO TAKE JUST A FEW MINUTES TO
2 REVIEW MY EXPERIENCE AND QUALIFICATIONS. I AM A
3 PHYSICIAN. I WAS TRIPLE BOARD CERTIFIED IN INTERNAL
4 MEDICINE, CARDIOVASCULAR DISEASES, AND
5 INTERVENTIONAL CARDIOLOGY. FROM 1986 TO 2000 I
6 CODIRECTED THE CARDIOVASCULAR INTERVENTION CENTER AT
7 CEDARS-SINAI. DURING THOSE YEARS I CARED FOR
8 LITERALLY THOUSANDS OF PATIENTS, CONDUCTED
9 PRECLINICAL AND CLINICAL RESEARCH, AND TAUGHT DOZENS
10 OF PHYSICIANS IN TRAINING FROM ALL LEVELS ALL THE
11 WAY FROM MEDICAL STUDENTS TO POSTDOCTORAL FELLOWS.

12 I WAS FORTUNATE TO HAVE ENTERED THE
13 SPECIALTY OF CARDIOLOGY DURING A PERIOD OF
14 UNPRECEDENTED INNOVATION. WHEN I BEGAN, THERE WERE
15 NO STATINS, NO STINTS, NO RESYNCHRONIZATION DEVICES,
16 NO MODERN ANTIPLATELET AGENTS, AND HEART ATTACKS
17 WERE MOSTLY TREATED SIMPLY WITH BEDREST. I HAVE
18 WITNESSED AND HAVE PLAYED A TINY PART IN A
19 SPECTACULAR TRANSFORMATION OF CARDIOVASCULAR
20 MEDICINE THAT HAS RESULTED IN REDUCED SUFFERING AND
21 MORTALITY ALL OVER THE WORLD.

22 THIS IS EVIDENCE THAT WITH COORDINATED,
23 DILIGENT RESEARCH, LINKING DISCOVERIES IN THE BASIC
24 SCIENCES TO PEOPLE AND ENTITIES THAT CAN TRANSLATE
25 THESE DISCOVERIES INTO CLINICAL PRODUCTS, MIRACLES

BARRISTERS' REPORTING SERVICE

1 CAN INDEED HAPPEN. AND THAT IS WHY I AM HERE TODAY.

2 I HAVE BEEN AN ACADEMIC AND CODIRECTED A
3 SUBSTANTIAL RESEARCH PROGRAM. I'M WELL PUBLISHED
4 AND HAVE PARTICIPATED IN ALL THE USUAL SCHOLARLY
5 ACTIVITIES OF GRANT WRITING, PEER REVIEW, AS WELL AS
6 THE INTERNATIONAL LECTURE CIRCUIT. I ACHIEVED THE
7 RANK OF FULL PROFESSOR AT THE UCLA SCHOOL OF
8 MEDICINE. MY RESEARCH WAS MOSTLY WHAT WE CALL TODAY
9 TRANSLATIONAL. I CONSIDER MYSELF A PRACTICAL
10 PERSON, AND MY INTEREST TO THIS DAY IS IN FINDING
11 NEW WAYS TO TREAT PATIENTS.

12 FROM MY EXPERIENCE AS AN ACADEMIC, I
13 LEARNED HOW TO BE AN INVESTIGATOR IN A CLINICAL
14 TRIAL, HOW TO STRUCTURE A TRIAL TO RIGOROUSLY TEST A
15 HYPOTHESIS, AND HOW TO DEAL WITH INSTITUTIONAL
16 REVIEW BOARDS. I HAVE WRITTEN RESEARCH GRANTS AND
17 WAS AN INVESTIGATOR ON SEVERAL NIH-FUNDED GRANTS AND
18 SEVERAL OTHERS FROM CORPORATIONS AND PHILANTHROPIC
19 ORGANIZATIONS. I LEARNED HOW TO CREATE AND REVIEW
20 GRANT BUDGETS AND, MORE IMPORTANTLY, AS RELATED TO
21 CIRM, HOW TO CRITICALLY REVIEW THEM FOR FISCAL
22 EFFICIENCY.

23 I LEARNED THE PROCESS OF PEER REVIEW. FOR
24 MANY YEARS I PROVIDED EXTERNAL REVIEW FOR SEVERAL
25 LEADING MEDICAL JOURNALS. I EDITED A BOOK IN THE

BARRISTERS' REPORTING SERVICE

1 FIELD OF INTERVENTIONAL CARDIOLOGY, AND I ORGANIZED
2 AND DIRECTED MANY COURSES FOR THE TEACHING OF
3 ADVANCES IN INTERVENTIONAL CARDIOLOGY TO
4 PRACTITIONERS FROM AROUND THE WORLD.

5 FINALLY, I HAVE BEEN AND REMAIN AN ACTIVE
6 ENTREPRENEUR IN THE LIFE SCIENCES SECTOR. I HAVE
7 FOUNDED AND SOLD SEVERAL COMPANIES, AND HAVE BEEN
8 CHAIRMAN AND CEO OF A NASDAQ TRADED PUBLIC COMPANY
9 THAT, PRIOR TO ITS SALE, HAD 300 EMPLOYEES IN
10 SEVERAL COUNTRIES. THESE INCLUDED SCIENTISTS AND
11 ENGINEERS AS WELL AS MANUFACTURING, CLINICAL,
12 REGULATORY, SALES, MARKETING, HUMAN RESOURCES,
13 ACCOUNTING, AND FINANCE PERSONNEL.

14 NO ENTREPRENEUR CAN SURVIVE WITHOUT
15 FUND-RAISING SKILLS. CAPITAL IS OXYGEN TO
16 TECHNOLOGY START-UPS JUST AS IT IS TO THIS AGENCY.
17 FUND-RAISING IS ABOUT SELLING A VISION. AND I HAVE
18 RAISED HUNDREDS OF MILLIONS OF DOLLARS OF CAPITAL IN
19 BOTH THE PRIVATE AND PUBLIC CAPITAL MARKETS. I
20 MIGHT SAY THAT OUR VENTURES ARE ALL HIGH RISK, AND
21 INVESTORS NEED TO BE CONVINCED OF THE MERITS OF
22 THESE VENTURES AS THEY ARE NOT BACK-STOPPED BY THE
23 FAITH AND CREDIT OF THE STATE OF CALIFORNIA.

24 I'VE INTERACTED WITH THE FDA AND FOREIGN
25 REGULATORY BODIES ON SEVERAL PROJECTS AND HAVE AN

BARRISTERS' REPORTING SERVICE

1 UNDERSTANDING OF THE REGULATORY AND CLINICAL
2 APPROVAL PROCESS. I'M VERY EXPERIENCED IN MATTERS
3 OF INTELLECTUAL PROPERTY AS RELATED TO PATENT
4 PROSECUTION, LITIGATION, AND LICENSING. JUST IN THE
5 LAST YEAR I HAVE BEEN A LISTED INVENTOR ON SEVERAL
6 NEW PATENT APPLICATION FILINGS. I HAD THE ULTIMATE
7 RESPONSIBILITY FOR A VERY CONTENTIOUS GLOBAL PATENT
8 LITIGATION AND HAVE RETAINED AND DIRECTED SOME OF
9 THE SHARPEST INTELLECTUAL PROPERTY ATTORNEYS AROUND
10 THE WORLD.

11 I REMAIN ENGAGED IN SEVERAL EARLY STAGE
12 LIFE SCIENCE TECHNOLOGY COMPANIES IN THE MEDICAL
13 DEVICE AND BIOTECHNOLOGY ARENAS. I VIEW THIS AS A
14 POSITIVE FOR THE PRESENT POSITION. THESE VENTURES
15 PERMIT ME TO STAY IN TOUCH WITH THE INDUSTRY IN A
16 VERY HANDS-ON MANNER.

17 MY INTEREST IN THE CIRM POSITION COMES
18 ONLY AFTER SUBSTANTIAL REFLECTION AS WELL AS
19 DISCUSSION WITH MANY PARTIES BOTH WITHIN CIRM AND ON
20 THE OUTSIDE. I BELIEVE THAT STEM CELL SCIENCE IS ON
21 THE CUSP OF IMPORTANT BREAKTHROUGHS, AND THEY WILL
22 REVOLUTIONIZE THE FIELD OF MEDICINE. AS I WAS
23 FORTUNATE TO BE INVOLVED IN THE CARDIOVASCULAR FIELD
24 AS IT WAS RAPIDLY EXPANDING, I WOULD BE PRIVILEGED
25 TO REPEAT THIS EXPERIENCE IN THE FIELD OF

BARRISTERS' REPORTING SERVICE

1 REGENERATIVE MEDICINE.

2 I BELIEVE IN PUBLIC SERVICE. I IMMIGRATED
3 TO THIS COUNTRY AND TO THIS STATE IN 1982. WHEN I
4 ARRIVED HERE, I HAD JUST A COUPLE OF THOUSAND
5 DOLLARS, AND I DID NOT KNOW ONE SINGLE PERSON IN
6 CALIFORNIA. I'M NOW FORTUNATE TO BE ABLE TO OFFER A
7 PORTION OF MY TIME AND MY 30 YEARS OF EXPERIENCE IN
8 MEDICINE AND THE LIFE SCIENCES AS A PUBLIC SERVICE
9 TO THE STATE AND THE COUNTRY THAT HAS GIVEN SO MUCH
10 TO ME.

11 ALLOW ME TO ADDRESS MY VISION OF THE ROLE
12 OF CHAIRMAN. I SEE THE ROLE OF CIRM AS A STIMULUS
13 TO INNOVATION AND TO CREATING A VIBRANT NEW MEDICAL
14 TECHNOLOGY INDUSTRY IN CALIFORNIA AND THE NATION.
15 THE STATE'S VOTERS HAVE IDENTIFIED THIS INITIATIVE
16 AS A HIGH PRIORITY. IDEALLY, THEN, THE CHAIRMAN OF
17 CIRM, AS BOTH ITS PUBLIC FACE AND ITS STRATEGIC
18 LEADER, WOULD POSSESS EXPERTISE AND EXPERIENCE IN
19 CONDUCT OF SCIENTIFIC RESEARCH, ITS FINANCING, AND
20 IN BRINGING BASIC SCIENCE TO INDUSTRIAL FRUITION.

21 AN ORGANIZATION THAT HAS TWO CHIEF
22 EXECUTIVES CARRIES WITH IT THE INTRINSIC POTENTIAL
23 FOR SERIOUS CHALLENGES. CIRM IS COMPOSED OF A
24 MULTITALENTED AND ENGAGED BOARD, A CHAIRMAN, TWO
25 SKILLED VICE CHAIRMEN, AND A FULL-TIME MANAGEMENT

BARRISTERS' REPORTING SERVICE

1 TEAM, INCLUDING A PRESIDENT.

2 THE ROLE OF THE PRESIDENT IS DAILY
3 MANAGEMENT. HE OR SHE MUST BE FREE TO PURSUE THIS
4 ROLE WITHOUT ENCUMBRANCE. THE FUNCTION OF CHAIRMAN,
5 ON THE OTHER HAND, IS NOT DAY-TO-DAY MANAGEMENT.
6 THE FIRST PRIORITY OF THE CHAIRMAN IS OVERSIGHT.
7 THE CHAIRMAN AS THE LEADER OF THE ICOC SHOULD APPLY
8 HIS TALENTS AND EXPERIENCE TO ASSURE THAT THE AGENCY
9 IS FUNCTIONING OPTIMALLY AND IN ACCORDANCE WITH ITS
10 MISSION. THIS WOULD INCLUDE PROVIDING DIRECTION,
11 ADVICE, AND COUNSEL TO MANAGEMENT, AS WELL AS
12 ASSURING ACCOUNTABILITY. THE OVERSIGHT MODEL ONLY
13 WORKS IF MANAGEMENT IS BOTH EMPOWERED AND
14 ACCOUNTABLE.

15 GIVING AWAY MONEY IS EASY. GIVING IT AWAY
16 WITH MAXIMUM IMPACT IS NOT. THE PUBLIC DESERVES AND
17 EXPECTS EXCELLENCE.

18 A CHAIRMAN MUST ALSO EFFECTIVELY
19 COLLABORATE WITH THE GOVERNOR'S OFFICE AND THE
20 TREASURER TO ASSURE THAT THE BOND MONIES ARE
21 AVAILABLE TO SUPPORT THE OPERATIONS AND THE
22 COMMITMENT OF THE AGENCY. WITH RESPECT TO THE
23 MUNICIPAL BOND MARKET IN CALIFORNIA, THESE ARE NO
24 ORDINARY TIMES. MUCH HAS RECENTLY BEEN SAID ABOUT
25 THE NEED FOR EXPERTISE IN BOND FINANCING. PERMIT ME

BARRISTERS' REPORTING SERVICE

1 TO TAKE A MOMENT TO OPEN THIS PARTICULAR BLACK BOX.
2 IN THE SPECTRUM OF FINANCIAL INSTRUMENTS,
3 STATE BONDS ARE NOT CONSIDERED COMPLICATED. IN
4 FACT, THEY ARE AMONGST THE MOST SIMPLE. WITH
5 RESPECT TO CIRM, THE PEOPLE, BY VIRTUE OF
6 PROPOSITION 71, HAVE PERMITTED THE STATE TO SELL
7 BONDS TO FUND THE AGENCY. THESE ARE SO-CALLED
8 GENERAL OBLIGATION BONDS AND ARE BACKED BY THE FAITH
9 AND CREDIT OF THE STATE. AS SUCH, THEY ARE TO BE
10 PAID BACK BY THE TAXING POWER OF THE STATE AND ARE
11 CONSIDERED VERY SAFE INVESTMENTS.

12 FURTHER, THE AGENCY IS AWAITING A RULING
13 FROM THE INTERNAL REVENUE SERVICE THAT WOULD MAKE
14 THESE BONDS EXEMPT FROM BOTH FEDERAL AND STATE
15 TAXES. IN ORDINARY TIMES THESE BONDS WOULD NOT BE
16 DIFFICULT TO SELL AS BOTH INDIVIDUALS AND
17 INSTITUTIONS VIEW THEM AS EXTREMELY CONSERVATIVE
18 INVESTMENTS.

19 UNFORTUNATELY, OUR STATE IS IN A CONDITION
20 OF FINANCIAL DISTRESS. WE'RE RUNNING LARGE
21 DEFICITS, AND THERE IS NEED FOR PAINFUL AND
22 POLITICALLY DIFFICULT DECISIONS.

23 AS OF THIS TIME, WE HAVE NO BUDGET FOR THE
24 CURRENT FISCAL YEAR. WITHOUT A BUDGET, IF
25 CALIFORNIA ATTEMPTED TO SELL BONDS, THE ISSUANCE

BARRISTERS' REPORTING SERVICE

1 WOULD RECEIVE A POOR CREDIT RATING, AND THE COST OF
2 BORROWING WOULD BECOME PROHIBITIVE. PUT VERY
3 SIMPLY, IF BONDS ARE VIEWED AS RISKY, THEN THE
4 INTEREST THAT MUST BE PAID GOES UP. FOR EXAMPLE,
5 LAST WEEK GREEK BONDS WERE PAYING 28 PERCENT
6 INTEREST. THIS WEEK THE RATES ARE DOWN A FEW
7 HUNDRED BASIS POINTS DUE TO THE RESCUE BY THE
8 EUROPEAN CENTRAL BANK.

9 THE STATE WILL NOT SELL BONDS UNTIL WE
10 HAVE A BUDGET. THIS SEEMS QUITE REASONABLE.
11 SELLING POORLY RATED BONDS WILL DRIVE UP THE COST OF
12 BORROWING, WHICH WILL THEN DEPRIVE THE GENERAL FUND
13 OF MUCH NEEDED CASH, THEREBY FURTHER PERPETUATING
14 THE NEED FOR PAINFUL CUTS AND INCREASED TAXES.
15 FORTUNATELY, CIRM HAS CASH RESERVES EVEN WITHOUT ANY
16 CHANGES IN SPENDING THAT PERMIT FUNDING UNTIL THE
17 SPRING OF 2012. FURTHER, THERE ARE CURRENTLY ABOUT
18 \$10 BILLION OF BOND PROCEEDS REMAINING IN THE STATE
19 COFFERS WHICH ARE AVAILABLE TO BE ALLOCATED TO
20 VARIOUS STATE AGENCIES. HOPEFULLY THE LEGISLATURE
21 WILL PASS A BUDGET AND THE GOVERNOR WILL SIGN IT
22 WELL BEFORE THE SPRING OF 2012. CIRM WILL THEN BE
23 ABLE TO RECEIVE AN ALLOCATION OF THE STATE BOND
24 SALES IN AN ORDINARY FASHION.

25 SHOULD THE UNTHINKABLE HAPPEN, AS IT

BARRISTERS' REPORTING SERVICE

1 OCCASIONALLY DOES, AND THERE BE NO BUDGET BY NEXT
2 YEAR, THEN CIRM WILL NEED TO ASSUME THE MENTALITY OF
3 A START-UP VENTURE AND GET CREATIVE IN ORDER TO MEET
4 ALL OF ITS OBLIGATIONS. ONE MIGHT CONSIDER A
5 PRIVATE PLACEMENT IF PERMITTED BY THE STATE. AS
6 WITH ANY FORM OF FINANCING, IT IS NOT THE MECHANICS
7 THAT IS RATE LIMITING. RATHER, IT IS THE ABILITY TO
8 CLEARLY ARTICULATE THE VISION TO THE PROSPECTIVE
9 INVESTORS.

10 CIRM IS FORTUNATE TO BE WELL STAFFED WITH
11 BIPARTISAN EXPERTS TO HELP IT WEATHER A POSSIBLE
12 STORM, INCLUDING ITS TWO VICE CHAIRS, SENATOR ART
13 TORRES AND DUANE ROTH, TO REPRESENT THE AGENCY
14 INTERESTS IN SACRAMENTO. THE BOARD COUNSEL, JAMES
15 HARRISON, THE GENERAL COUNSEL, ELONA BAUM, AND YET
16 TO BE RETAINED CFO WILL PROVIDE EXPERT LEGAL AND
17 FINANCIAL LEADERSHIP. THIS IS NOT TO MENTION THE
18 OTHER LEGAL CONSULTING OR BANKING TALENT THAT CAN BE
19 CALLED ON IN AN EMERGENCY.

20 LADIES AND GENTLEMEN, THERE'S NO ONE
21 PERSON WHO WILL MASTER ALL THE AREAS OF CIRM
22 REFINANCING, INCLUDING THE CRITICAL ISSUES OF
23 TAXATION. RATHER, CIRM LEADERSHIP NEEDS TO MANAGE
24 THE PROCESS BY USING SKILLED PROFESSIONALS WITH
25 SPECIFIC AREAS OF EXPERTISE. I AM HIGHLY

BARRISTERS' REPORTING SERVICE

1 EXPERIENCED AT MANAGING TEAMS OF EXPERTS IN ORDER TO
2 EXECUTE COMPLEX LEGAL AND FINANCIAL TRANSACTIONS.

3 THE NEXT CHAIRMAN WILL SURELY NEED TO
4 SHORE UP THE AGENCY'S MESSAGING. THE PUBLIC IS
5 WAITING TO HEAR WHAT IS BEING DONE WITH THEIR MONEY.
6 PATIENTS ARE WAITING TO HEAR WHAT IT IS -- WHEN IT
7 IS THAT SCIENCE WILL DELIVER THE LIFE-SAVING
8 THERAPIES THEY HAVE BEEN HOPING FOR. I WOULD
9 RECOMMEND TAPPING THE FORMIDABLE TALENTS ON THE ICOC
10 AS WELL AS THOSE OUTSIDE OF CIRM WHO WOULD PROVIDE
11 EX OFFICIO SERVICE WITH RESPECT TO BRAND AND
12 MOVEMENT MOMENTUM. NO PLACE ON EARTH HAS MORE
13 EXPERTISE IN THIS AREA THAN DOES CALIFORNIA.

14 FINALLY, THE CHAIRMAN NEEDS TO TAKE A
15 LEADERSHIP ROLE IN SETTING THE STRATEGY BY
16 COLLABORATING WITH OTHER STAKEHOLDERS. THIS IS,
17 AFTER ALL, A DYNAMIC FIELD THAT REQUIRES REAL-TIME
18 ADJUSTMENTS OF THE GAME PLAN.

19 THE MOST IMPORTANT STRATEGIC COMPARATIVE
20 AT THE PRESENT TIME IS TO GET NEW PRODUCTS INTO THE
21 CLINIC. CIRM NEEDS NOT ONLY TO FUND PROMISING
22 RESEARCH, BUT ALSO TO FACILITATE THE TRANSLATION OF
23 PROMISING THERAPIES FROM THE LABORATORY. AT THIS
24 STAGE CIRM MIGHT BE WELL ADVISED TO CONSIDER FURTHER
25 MECHANISMS OF BEING PROACTIVE IN THIS REGARD.

BARRISTERS' REPORTING SERVICE

1 WITHOUT GETTING INTO DETAIL, THE AGENCY COULD
2 CONTEMPLATE DEVELOPING A CORE EXPERTISE IN
3 PRECLINICAL AND REGULATORY AFFAIRS. IT SHOULD
4 CONSIDER DEVELOPING A PUBLICLY AVAILABLE REPOSITORY
5 OF EXPERTISE AND DATA SO AS TO ASSURE THAT EACH NEW
6 FDA TRIAL APPLICANT IS NOT REINVENTING THE WHEEL AND
7 WASTING PRECIOUS TIME AND MONEY.

8 IT IS A WIDELY HELD BELIEF IN THE LIFE
9 SCIENCE INDUSTRY THAT INNOVATION IS BEING NEGATIVELY
10 IMPACTED BY A SOMETIMES ONEROUS, UNCERTAIN, AND
11 UNPREDICTABLE REGULATORY PROCESS. IN MY EXPERIENCE,
12 INTELLIGENT AND GENUINELY WELL-INTENTIONED PUBLIC
13 SERVANTS STAFF THE FDA. THEY DO, HOWEVER, WORK FOR
14 THE ADMINISTRATION AND ARE FUNDED BY CONGRESS. AS
15 SUCH, THEY FOLLOW THE LAW AS WELL AS THE DIRECTION
16 OF THE ADMINISTRATION.

17 CIRM LEADERSHIP AND ITS ALLIES MUST TAKE A
18 PIVOTAL ROLE IN FACILITATING THE INTERACTIONS OF
19 THERAPY INNOVATORS WITH FDA. I BELIEVE THAT THE
20 ENGINE OF AMERICAN LIFE SCIENCE CREATIVITY IS IN
21 JEOPARDY. IT IS NOW TIME TO EXPLORE NEW PARADIGMS
22 FOR EVALUATION AND APPROVAL OF NEW THERAPIES. CIRM
23 IS UNIQUELY POSITIONED TO BE A DRIVER OF THIS
24 EFFORT. WHILE CIRM WILL ALWAYS STAND FOR SAFETY AND
25 GOOD SCIENCE, WHEN IT COMES TO CRITICAL AND

BARRISTERS' REPORTING SERVICE

1 LIFE-THREATENING ILLNESSES, PATIENTS SHOULD HAVE A
2 MORE ACTIVE ROLE IN THEIR OWN THERAPEUTIC OPTIONS.
3 THE AGENCY CAN BE A LEADER IN THE AREA OF REGULATORY
4 REFORM AND, AS SUCH, HASTEN DELIVERY OF MUCH NEEDED
5 THERAPIES.

6 THE CELL THERAPY INDUSTRY IS NASCENT, AND
7 THE CAPITAL MARKETS HAVE NOT RECENTLY BEEN KIND TO
8 IT. CIRM NEEDS TO ENHANCE ITS COMMERCIAL
9 RELATIONSHIPS AS MOST NEW THERAPIES WILL REQUIRE A
10 COMMERCIAL ENTITY IN ORDER TO REACH PATIENTS. I
11 WOULD LIKE TO SEE CIRM ACT AS A FACILITATOR. OUR
12 STATE IS REplete WITH INVESTORS LOOKING FOR WORTHY
13 INVESTMENTS. WE ARE SIMILARLY RICH WITH YOUNG
14 COMPANIES LOOKING FOR THESE VERY INVESTORS. WE HAVE
15 TO HELP THE PARTIES FIND EACH OTHER. SOMETHING AS
16 SIMPLE AS A QUARTERLY OR BIANNUAL SEMINAR FOR
17 VENTURE CAPITALISTS AND OTHER POTENTIAL INVESTORS
18 WITH PROMISING COMPANIES PRESENTING THEIR BUSINESS
19 PLANS COULD BE HIGHLY IMPACTFUL. IT COULD DRIVE THE
20 ENTIRE FIELD AND PERMIT GROWTH IN THIS STATE'S
21 BIOTECHNOLOGY SECTOR.

22 A FURTHER CREATIVE OPPORTUNITY MIGHT BE
23 FOR CIRM TO SELL SOMETHING CALLED INDUSTRIAL
24 DEVELOPMENT BONDS. THESE ARE A TYPE OF PUBLIC BOND
25 SPECIFICALLY INTENDED FOR BUILDING BUSINESSES OR

BARRISTERS' REPORTING SERVICE

1 INDUSTRIES IN A REGION. THESE FUNDS, BORROWED USING
2 THE CREDIT OF THE STATE, COULD THEN BE RELENDED TO
3 LESS CREDIT WORTHY, BUT SCIENTIFICALLY WORTHY
4 CALIFORNIA COMPANIES TO HELP PAY FOR MUCH NEEDED
5 CLINICAL TRIALS. ONE COULD ATTACH PROVISIONS THAT
6 RETURN SOME OF THE UPSIDE TO THE STATE OR THE
7 LENDERS. CIRM COULD, THEREFORE, ATTRACT SOCIALLY
8 CONSCIOUS INVESTORS AND ACT AS A WHAT WE CALL
9 VENTURE LENDER.

10 THIS IS A VERY WELL-DEVELOPED MODEL IN THE
11 FOR-PROFIT SECTOR. FOR EXAMPLE, SILICON VALLEY BANK
12 DOES IT ALL THE TIME. CIRM MIGHT WELL CONSIDER SOME
13 ADAPTATION OF THIS MODEL.

14 THE PRIMARY MISSION OF CIRM IS TO EXPEDITE
15 THE DEVELOPMENT AND DELIVERY OF NEW THERAPIES FOR
16 THOSE SUFFERING FROM CHRONIC AND DEBILITATING AND
17 FATAL ILLNESSES. THE AGENCY DOES NOT CONDUCT
18 RESEARCH, NOR DOES IT TREAT PATIENTS. CIRM NEEDS TO
19 KEEP ITS EYE ON THE BALL. ITS JOB IS IN THEORY
20 QUITE SIMPLE. PROPOSE THE BEST RFAS, BET ON THE
21 MOST PROMISING SCIENCE, AND THEN USE ITS RESOURCES
22 TO FACILITATE THE MOVEMENT OF THESE PRODUCTS INTO
23 THE CLINIC. NOTHING MORE, NOTHING LESS.

24 THE PEOPLE OF CALIFORNIA AGREED TO SPEND
25 SEVERAL BILLION DOLLARS TO FUND THIS GRAND

BARRISTERS' REPORTING SERVICE

1 EXPERIMENT. THE OPPORTUNITY IS A HISTORIC ONE, AND
2 THE STAKES ARE HIGH. CIRM HAS NO TIME FOR
3 BICKERING. THOUGH THIS IS AN INTRINSICALLY
4 POLITICAL ORGANIZATION, I HAVE NO POLITICAL DEBTS TO
5 PAY. IF I WERE TO BE CHAIRMAN, I WOULD PLEDGE TO
6 YOU THAT I WILL ACT SOLELY FOR THE BEST INTEREST OF
7 PATIENTS.

8 I HAVE YEARS OF EXPERIENCE IN
9 TRANSLATING SCIENCE INTO PRODUCTS. I HAVE CONDUCTED
10 NUMEROUS FINANCINGS, LED ORGANIZATIONS OF SCIENTISTS
11 AND ENGINEERS, MANAGED COMPLEX LEGAL MATTERS, AND
12 BEEN ABLE TO EFFECTIVELY ARTICULATE FUTURISTIC
13 CONCEPTS TO INVESTORS. IT IS NOW TIME TO GET ALL
14 HANDS ON DECK, PULL TOGETHER, AND EXECUTE THE
15 MISSION FOR WHICH CIRM WAS CONCEIVED. I WOULD BE
16 HONORED TO SERVE AS CHAIRMAN OF THIS AGENCY AND TO
17 LEAD CIRM INTO ITS NEXT STAGE, DELIVERING THERAPIES
18 TO THE MILLIONS OF PEOPLE SUFFERING FROM INCURABLE,
19 DEBILITATING, AND FATAL ILLNESSES. THANK YOU VERY
20 MUCH FOR YOUR TIME.

21 (APPLAUSE.)

22 CHAIRMAN KLEIN: AND THANK YOU, DR.
23 LITVACK, FOR YOUR EXTRAORDINARY CAREER AND
24 INNOVATIONS IN MEDICINE.

25 JON THOMAS.

BARRISTERS' REPORTING SERVICE

1 MR. THOMAS: THANK YOU, FRANK. THAT WAS
2 VERY INSPIRING.

3 MEMBERS OF THE ICOC AND THE PUBLIC, MY
4 NAME IS JONATHAN THOMAS. I APPRECIATE THE
5 OPPORTUNITY TO ADDRESS YOU TODAY AS ONE OF THE
6 CANDIDATES FOR THE CHAIR POSITION AT THE CALIFORNIA
7 INSTITUTE FOR REGENERATIVE MEDICINE OR CIRM. FOR A
8 PERSON WITH MY BACKGROUND AND INTERESTS, I TRULY
9 VIEW THIS AS THE OPPORTUNITY TO CONTRIBUTE OF A
10 LIFETIME. I AM GRATEFUL FOR THE CONFIDENCE THAT THE
11 GOVERNOR, LIEUTENANT GOVERNOR, AND STATE TREASURER
12 HAD IN NOMINATING ME FOR THIS POST.

13 I CONGRATULATE FRANK FOR BEING NOMINATED
14 AS WELL AND WISH HIM WELL AS WE REACH THE END OF
15 THIS PROCESS.

16 MY QUEST FOR THIS JOB BEGAN YEARS AGO EVEN
17 THOUGH I DIDN'T KNOW IT AT THE TIME. AS A PREMED
18 YALE-TRAINED BIOLOGIST, I HAVE CLOSELY TRACKED
19 DEVELOPMENTS IN RECOMBINANT DNA, GENETIC
20 ENGINEERING, GENOMICS, STEM CELLS, AND OTHER HOT
21 AREAS OF BIOLOGICAL RESEARCH. WHILE MY CAREER HAS
22 BEEN PRINCIPALLY IN FINANCE, MOST RECENTLY AS A
23 COFOUNDER IN 1990 OF AN INVESTMENT BANK AND PRIVATE
24 EQUITY FIRM CALLED SAYBROOK CAPITAL, I HAVE ALWAYS
25 LOOKED TO RETURN TO BIOLOGY IF THE RIGHT OPPORTUNITY

BARRISTERS' REPORTING SERVICE

1 PRESENTED ITSELF. THIS JOB IS THAT OPPORTUNITY.

2 BEFORE I CONTINUE, I TOO WOULD LIKE TO SAY
3 A FEW WORDS ABOUT BOB KLEIN. SIMPLY PUT, WE
4 WOULDN'T BE HERE TODAY AND THE MEDICAL WORLD WOULD
5 BE A LESSER PLACE BUT FOR HIS EFFORTS. I WANT TO
6 CONGRATULATE BOB ON HIS VISION, DEDICATION, AND
7 TIRELESS WORK IN CREATING A PREEMINENT MODEL FOR
8 SCIENTIFIC RESEARCH FUNDING. AT HIS INITIATIVE AND
9 THROUGH HIS AND THE BOARD'S EXTRAORDINARY EFFORTS
10 AND THOSE OF THE PRESIDENT AND HIS STAFF, CIRM HAS
11 BECOME THE LARGEST SOURCE FOR STEM CELL RESEARCH IN
12 THE WORLD.

13 HAVING BEEN THROUGH TWO EVALUATION
14 SUBCOMMITTEE INTERVIEWS, COPIES OF WHICH ARE ON THE
15 TABLE OVER HERE, I THINK YOU HAVE A SENSE OF MY
16 QUALIFICATIONS FOR THE JOB. PUBLIC FINANCE
17 INVESTMENT BANKER, PATIENT ADVOCATE, BIOLOGIST, STEM
18 CELL FINANCIER, PUBLIC AGENCY EXECUTIVE, LAWYER, AND
19 VETERAN OF GOVERNMENT AFFAIRS.

20 I WOULD LIKE TO DIVERGE A BIT FROM MY
21 EARLIER REMARKS AND GIVE YOU MY THOUGHTS ON THE
22 STATE OF THE ENTERPRISE AT CIRM AND WHAT I BELIEVE
23 THE ORGANIZATION NEEDS GOING FORWARD. FROM A MACRO
24 PERSPECTIVE, THE AGENCY HAS BEEN A HUGE SUCCESS. IT
25 HAS AWARDED OVER \$1.25 BILLION IN GRANTS OR LOANS TO

BARRISTERS' REPORTING SERVICE

1 CUTTING-EDGE RESEARCH AIMED AT CURING A HOST OF
2 PRESENTLY INCURABLE DISEASES. FROM THE LIKES OF UC
3 BERKELEY, SONG LI, PIONEERING WORK ON IPS CELLS AND
4 TISSUE REGENERATION, TO USC'S PAULA CANNON AND CITY
5 OF HOPE'S JOHN ZAIA AND THEIR COMBINED WORK ON BLOOD
6 FORMING STEM CELLS IN HIV RESISTANT T-CELLS, TO
7 UCSF'S ROBERT BLALOCK AND HIS WORK ON THE ROLE OF
8 MICRO-RNA'S IN STEM CELL BIOLOGY IN CANCER FOR WHICH
9 HE WAS JUST GIVEN THE YOUNG INVESTIGATOR AWARD BY
10 THE ISSCR, TO STANFORD'S IRV WEISSMAN AND MARIUS
11 VERNIG, AND THE RESPECTIVE WORK ON AN ANTIBODY-BASED
12 DRUG TO TREAT LEUKEMIA AND CONVERTING HUMAN SKIN
13 CELLS INTO NEURONS THROUGH TRANSDIFFERENTIATION, THE
14 FUNDED SCIENTISTS AT CIRM ARE RESEARCHING POTENTIAL
15 THERAPIES WITH EXCEPTIONAL PROMISE.

16 CIRM HAS ATTRACTED 880 MILLION IN
17 SUPPLEMENTAL PRIVATE DONATIONS THAT HAS HELPED BUILD
18 12 STATE-OF-THE-ART RESEARCH INSTITUTES. AS THE
19 GO-TO AGENCY THAT EVERYONE WANTS TO DEAL WITH THAT
20 HAS ENTERED INTO 12 COLLABORATIVE AGREEMENTS WITH
21 NATIONS AND STATES, PUTTING UP THE BEST AND THE
22 BRIGHTEST STEM CELL SCIENTISTS THEY HAVE TO OFFER.
23 ALL OF THESE ACTS PAINT A PICTURE OF TRUE
24 ACCOMPLISHMENT AND COMBINE TO FORM AN EVOLVING
25 CONTRIBUTION TO MEDICAL SCIENCE OF ENORMOUS

BARRISTERS' REPORTING SERVICE

1 PROPORTIONS.

2 HAVING SAID ALL THAT, CIRM IS AT A
3 CRITICAL CROSSROADS IN ITS HISTORY. AS THE EVENTS
4 OF THE PAST WEEK CONTINUE TO REMIND US, CALIFORNIA
5 IS IN A STATE OF FULL-OUT FISCAL CRISIS. NO ONE
6 KNOWS WHEN IT WILL END OR HOW IT WITH ULTIMATELY
7 PLAY OUT. AS A RESULT, THE AGENCY FACES THE REAL
8 POSSIBILITY THAT IT WILL NOT HAVE TIMELY ACCESS TO
9 THE AMOUNT OF BOND PROCEEDS IT EXPECTED AND MAY BE
10 FORCED TO LOOK ELSEWHERE IN VERY SHORT ORDER TO GET
11 THE FULL FUNDING REQUIRED TO MEET ITS PROJECTED
12 SHORT-TERM NEEDS OR TO EVALUATE HOW TO PUSH GRANTS
13 OUT OR OTHERWISE MODIFY EXPENSES IF THAT BECOMES
14 NECESSARY.

15 AND LET'S NOT KID OURSELVES. THIS PROBLEM
16 COULD LAST FOR A LONG TIME. AS A RESULT, THE MEDIUM
17 AND LONG-TERM FUNDING QUESTIONS ARE NO LESS
18 PROFOUND. AS THE AGENCY ENTERS A TRANSLATIONAL
19 PHASE WITH THE GOAL OF GETTING MORE AND MORE
20 PRODUCTS INTO CLINICAL TRIALS, WILL CIRM BE ABLE TO
21 HELP ITS GRANTEE AND LOAN RECIPIENTS GET THE MONEY
22 THEY NEED TO COVER THIS MOST EXPENSIVE PART OF
23 THERAPY DEVELOPMENT? WILL CIRM BE ABLE TO LINE UP
24 FUNDING TO SUSTAIN IT BEYOND THE TARGETED LAST AWARD
25 OF 2017? THESE ARE HUGE QUESTIONS.

BARRISTERS' REPORTING SERVICE

1 ON OTHER FRONTS, THE AGENCY IS IN THE
2 MIDDLE OF A COMMUNICATIONS WAR. IN SPITE OF ITS
3 GREAT STORY, THE WORLD SEEMS TO BE FOCUSED ON
4 INTERNAL ISSUES INSTEAD OF THE GRAND BIG PICTURE.
5 THESE NEGATIVE IMPRESSIONS DISTRACT FROM CIRM'S
6 MISSION AND UNNECESSARILY CREATE ADVERSARIES WHERE
7 THERE WOULD BE MANY FEWER IF THE TRUE STORY WERE
8 KNOWN.

9 FOR THAT REASON, CIRM MUST MOUNT A ROBUST
10 PUBLIC COMMUNICATIONS AND INFORMATION EFFORT TO GET
11 THE MESSAGE OUT. FRONT AND CENTER IN ANY PUBLIC
12 COMMUNICATION STRATEGY MUST BE THE PATIENT ADVOCATES
13 AND THEIR VAST NETWORKS. THESE ARE THE PEOPLE THAT
14 IT'S ALL ABOUT. WHEN YOU TELL THEIR STORIES, YOU
15 PUT A REAL LIFE FACE ON THE MARVELOUS SCIENCE AND
16 CANNOT HELP BUT COMPEL PUBLIC ENTHUSIASM AND
17 COMPASSION.

18 THE STEM CELL BUSINESS IS FRAUGHT WITH
19 LEGAL LAND MINES. WHETHER IT'S CHALLENGES TO
20 CONSTITUTIONALITY, REGULATORY CONCERNS, INTELLECTUAL
21 PROPERTY MATTERS, ADVERSE OPINIONS AT THE FEDERAL OR
22 INTERNATIONAL LEVEL AFFECTING THE VIABILITY OF STEM
23 CELL RESEARCH, CONTRACTUAL MATTERS BETWEEN FUNDERS
24 AND GRANTEES, DISPUTES BETWEEN ACADEMIC INSTITUTIONS
25 AND PRIVATE CORPORATIONS, OR OTHER ISSUES THAT WILL

BARRISTERS' REPORTING SERVICE

1 ARISE GOING FORWARD, ORGANIZATIONS LIKE CIRM MUST BE
2 EVER VIGILANT AND PROACTIVE TO KEEP ONE STEP AHEAD
3 OF THE LEGAL GAME.

4 OF THESE LEGAL ISSUES, REGULATORY AND
5 INTELLECTUAL PROPERTY ARE MATTERS THAT ARE
6 PARTICULARLY PRESSING. AT THIS POINT THERE IS NO
7 REGULATORY CERTAINTY FOR STEM CELL APPLICANTS TO THE
8 FDA. WE NEED PROTOCOLS AND BENCHMARKS FOR THE USE
9 OF STEM CELLS AS THERAPEUTIC AGENTS THAT EVERYONE
10 CAN LOOK TO AS THEY PURSUE PHASE I AND PHASE II
11 CLINICAL TRIALS, A CLEAR PATH TO APPROVAL, IF YOU
12 WILL.

13 ON THE INTELLECTUAL PROPERTY FRONT, A
14 WHOLE HOST OF ISSUES FROM THE DIFFERENCE IN OUR
15 PATENT LAWS AND THOSE OF OUR INTERNATIONAL
16 COLLABORATORS TO THE PENDING PATENT LEGISLATION IN
17 CONGRESS TO IP ISSUES THAT MAY CROP UP IN THE
18 CLINICAL TRIAL PHASE, ALL MUST GET IMMEDIATE
19 ATTENTION.

20 AS A STATE AGENCY, CIRM OPERATES IN A
21 PUBLIC AND INEVITABLY POLITICAL FISHBOWL. A VARIETY
22 OF STATE AND FEDERAL OFFICIALS HAVE JURISDICTION AND
23 EXPECT THE AGENCY TO PERFORM ON THE CUTTING EDGE
24 WITH INTEGRITY, TRANSPARENCY, AND PRUDENCE AS
25 GUARDIANS OF THE PUBLIC FUNDS. AS SENATOR TORRES

BARRISTERS' REPORTING SERVICE

1 AND DUANE ROTH KNOW SO WELL, THERE WILL ALWAYS BE A
2 NEED TO EFFECTIVELY INFORM THE PUBLIC AND THEIR
3 ELECTED REPRESENTATIVES ABOUT WHAT'S GOING ON AT
4 CIRM. SUCH COMMUNICATION IS CENTRAL TO HELPING
5 THOSE OFFICIALS HELP CIRM PURSUE ITS GOALS AND TO
6 INFORMING THEM AS THEY EXERCISE OVERSIGHT OVER THIS
7 AGENCY.

8 AT THIS STAGE IN CIRM'S LIFE, INDUSTRY
9 MUST NOW BECOME MORE ENGAGED. TO DATE ONLY 7
10 PERCENT OF AWARDED MONIES HAVE GONE TO INDUSTRY
11 APPLICANTS, ALTHOUGH SUBSTANTIAL ADDITIONAL AWARDS
12 WILL BE SHARED WITH BIOTECH MEMBERS OF THE APPROVED
13 DISEASE TEAMS THAT ARE SO BIG A PART OF CIRM'S
14 THERAPEUTIC PURSUIT. AS INDUSTRY REPRESENTS THE
15 ULTIMATE SOURCE FOR TAKE-OUT FINANCING FOR MANY OF
16 THESE GRANTEES AND THE MEANS TO HELP RESEARCHERS DO
17 EVERYTHING FROM TOXICITY TESTING TO LARGE-SCALE
18 MANUFACTURING TO BEING A PIVOTAL PLAYER ON DISEASE
19 TEAMS, BIOTECHNOLOGY COMPANIES NEED TO BE MUCH MORE
20 INVOLVED IN THE CIRM PROCESS GOING FORWARD.

21 YES, THE CHALLENGES FACING CIRM ARE MANY.
22 IF YOU DON'T CONFRONT THEM ALL HEAD-ON, THE CHANCES
23 OF IMPROVING ON THE AGENCY'S CONSIDERABLE SUCCESS
24 DIMINISH SIGNIFICANTLY. THE QUESTIONS BEFORE YOU
25 ARE WHO SHALL LEAD THAT FIGHT AND WHO IS BEST

BARRISTERS' REPORTING SERVICE

1 QUALIFIED FOR THE JOB?

2 ACTUALLY PROPOSITION 71 ANTICIPATED THESE
3 QUESTIONS. IT IS NO COINCIDENCE THAT THE STATUTE
4 REQUIRES THAT THE CHAIR BE IN CHARGE OF ALL EXTERNAL
5 FUNDING, LEGAL, GOVERNMENTAL, AND PUBLIC
6 COMMUNICATION CONCERNS, AS WELL AS TO LEAD THE BOARD
7 IN EXERCISING OVERSIGHT OVER THE AGENCY AND ITS
8 OPERATIONS. THAT PERSON MUST BE VERSED IN STEM CELL
9 SCIENCE, PUBLIC FINANCE, LAW, REGULATORY MATTERS,
10 GOVERNMENT AGENCY PROTOCOL, POLITICS, AND BE A
11 PATIENT ADVOCATE OF MANY YEARS STANDING.

12 IN LISTING THESE REQUIREMENTS, THE STATUTE
13 IMPOSES A VERY SUBSTANTIAL WORKLOAD ON THE POSITION.
14 IT REQUIRES OF CIRM'S LEADER THAT HE OR SHE BE
15 CAPABLE OF MANY THINGS AT ONCE, WORK WHICH BOB HAS
16 SHOWN CAN REALISTICALLY TAKE ALL THE TIME YOU'VE GOT
17 AND MORE. AT THE SAME TIME THE STATUTE DEFINES
18 SIMILAR SIZE RESPONSIBILITIES FOR THE PRESIDENT. HE
19 OR SHE MUST PROVIDE VISION AND LEADERSHIP AS WELL AS
20 OVERSEE THE SCIENTIFIC EFFORT AT THE CORE OF CIRM'S
21 MISSION. HE OR SHE MUST LEAD IN SOURCING GRANT AND
22 LOAN APPLICANTS, WORKING WITH PEER REVIEW TO
23 EVALUATE THE SCIENCE AND MONITOR GRANTS AND LOANS
24 ONCE MADE. HE OR SHE MUST ATTEND TO ALL INTERNAL
25 BUDGETING MATTERS IN ADDITION. ALTOGETHER, A VERY

BARRISTERS' REPORTING SERVICE

1 FULL-TIME JOB.

2 ON READING THE STATUTE, THE POSITIONS OF
3 CHAIR AND PRESIDENT ARE DESIGNED TO BE
4 COMPLEMENTARY, NOT OVERLAPPING. WHEN CARRIED OUT AS
5 DEFINED IN A COLLABORATIVE AND RESPECTFUL MANNER,
6 THEY SHOULD TOGETHER PROVIDE 100 PERCENT OF WHAT THE
7 AGENCY NEEDS TO BE EFFECTIVE.

8 ON THIS LATTER POINT SOME HAVE DECRIED
9 HAVING TWO CHIEF EXECUTIVES. I COULDN'T AGREE MORE.
10 IF ELECTED, I WOULD ATTEND TO MY MANY
11 RESPONSIBILITIES AND WOULD EXPECT ALAN TO DO THE
12 SAME. I WOULD NOT LOOK TO MICROMANAGE, BUT WOULD
13 INSTEAD EMPOWER ALAN TO HANDLE HIS CONSIDERABLE JOB
14 DUTIES. HE AND I SPOKE ON SUNDAY ON THIS VERY ISSUE
15 AND AGREED THAT A COMPLIMENTARY, HIGHLY
16 COLLABORATIVE RELATIONSHIP WAS THE BEST WAY TO BRING
17 THE AGENCY TOWARDS FULFILLING ITS GOALS.

18 I'VE ALSO HEARD THAT THE NEXT STAGE IS ALL
19 ABOUT GETTING POTENTIAL THERAPIES THROUGH PHASE I
20 AND II CLINICAL TRIALS. WHILE THERE IS NO QUESTION
21 THAT THIS IS ABSOLUTELY CRITICAL WORK CENTRAL TO
22 CIRM'S SUCCESS AS AN ONGOING ENTITY, NONE OF THIS
23 WILL BE POSSIBLE WITHOUT FUNDING AND FULL ATTENTION
24 TO THE OTHER SPECIFIC JOB RESPONSIBILITIES AND MANY
25 DAY-TO-DAY TASKS ASSOCIATED WITH THOSE DUTIES.

BARRISTERS' REPORTING SERVICE

1 I WOULD ALSO NOTE THAT WE CAN'T LOSE SIGHT
2 OF THE NEED FOR CONTINUED FUNDING FOR BASIC
3 RESEARCH. WITHOUT CONTINUING TO BUILD THAT
4 INFORMATION STOCKPILE, WE RISK HASTY DECISIONS ON
5 ADVANCED RESEARCH AND USING SHORTCUTS THAT COULD
6 TRIGGER BAD RESULTS AND UNNECESSARY SETBACKS.

7 WITH ALL OF THIS IN MIND, WHICH OF US IS
8 THE BEST CHOICE FOR THE NEXT CHAIR? IN HIS OPENING
9 STATEMENT TO THE EVALUATION SUBCOMMITTEE ON JUNE 3D,
10 FRANK STRESSED OVERSIGHT AS HIS FIRST OF SEVERAL
11 PRIORITIES AND HIS, QUOTE, BELIEF THAT THE
12 CHAIRMAN'S ROLE IS BEST ACCOMPLISHED BY A LEADER ON
13 A PART-TIME BASIS, CLOSE QUOTE. HE POINTS TO THE
14 BOARD AND STAFF TO HELP ADDRESS EXTERNAL FINANCIAL
15 AND POLITICAL MATTERS AS WELL AS TO OTHER LEGAL
16 CONSULTING OR BANKING TALENT THAT CAN BE CALLED IN
17 IF NEED BE.

18 LADIES AND GENTLEMEN, I SUBMIT WITH ALL
19 DUE RESPECT, AND I DO HAVE GREAT RESPECT, THAT THE
20 POSITION DEMANDS MORE THAN THAT. TO REITERATE,
21 THESE ARE PERILOUS ECONOMIC TIMES. UNLESS CIRM HAS
22 FUNDING IN THE NEAR, MEDIUM, AND LONG TERM, IT WOULD
23 BE HAMSTRUNG IN ITS EFFORT TO EFFECTIVELY MEET ITS
24 MISSION. YOU HOPE THE ANNUAL BOND ALLOCATION WILL
25 MEET YOUR DRAW-DOWN NEEDS AND THAT THE VOTERS WILL

BARRISTERS' REPORTING SERVICE

1 SEE FIT TO APPROVE A SUBSEQUENT BOND MEASURE DOWN
2 THE ROAD, BUT YOU HAVE TO BE PREPARED. YOU NEED TO
3 HAVE CREATIVE STRATEGIES IN YOUR BACK POCKET TO
4 ENSURE THAT FUNDS WILL BE THERE.

5 I BELIEVE THAT MY 25 YEARS IN PUBLIC
6 FINANCE AND PRIVATE EQUITY AND RAISING BILLIONS OF
7 DOLLARS OVER THAT PERIOD OF TIME POSITIONS ME TO
8 BEST DEAL WITH THIS MOST THRESHOLD OF ISSUES. THE
9 STATUTE THE VOTERS APPROVED CLEARLY CONTEMPLATES
10 THAT YOU WOULD BE BEST SERVED BY A CHAIR EXPERIENCED
11 IN ALL OF THE REQUIRED SKILL SETS AND ONE THAT COULD
12 AND WOULD SPEND MOST, IF NOT ALL, OF HIS TIME ON THE
13 JOB. HE SHOULD COMPLEMENT THE EXTRAORDINARY
14 STRENGTHS OF THE BOARD, A BOARD THAT, AMONG OTHER
15 THINGS, CURRENTLY INCLUDES A FORMER FDA
16 COMMISSIONER, A FORMER GENERAL COUNSEL TO ONE OF THE
17 LARGEST BIOTECH FIRMS WHO IS WELL VERSED IN THIS
18 NUANCE OF INTELLECTUAL PROPERTY AND THE PURSUIT OF
19 REGULATORY APPROVAL, AND MANY INDIVIDUALS IN BOTH
20 THE PUBLIC AND PRIVATE SECTORS WITH SPECIFIC
21 EXPERIENCE IN DEVELOPING THERAPIES.

22 YOU HAVE HEARD THAT I MEET ALL EIGHT
23 STATUTORY CRITERIA FOR THE CHAIR POSITION AND HAVE
24 USEFUL, RELEVANT, AND DIRECT EXPERIENCE IN EVERY
25 RESPONSIBILITY OUTLINED IN THE JOB DESCRIPTION.

BARRISTERS' REPORTING SERVICE

1 ABOVE ALL, I AM ENTIRELY COMMITTED TO YOUR SUCCESS
2 AND TO SUCCESS FOR THE PEOPLE OF CALIFORNIA IN
3 COMPLETING THE MISSION THEY GAVE YOU TO FIND ANSWERS
4 THAT WILL SAVE LIVES, EXTEND LIVES, AND IMPROVE THE
5 QUALITY OF LIVES OF EVERYONE WE CAN REACH WITH
6 HEALING THERAPIES. ADD IT ALL UP AND I BELIEVE I AM
7 THE BEST CHOICE TO BE YOUR NEXT CHAIR. I WOULD BE
8 HONORED TO WORK WITH YOU AND THE STAFF IN THAT
9 CAPACITY AND TO HELP TAKE THE AGENCY TO THE NEXT
10 LEVEL OF EXCELLENCE AND ACCOMPLISHMENT.

11 I THANK YOU FOR HEARING ME OUT AND WOULD
12 APPRECIATE YOUR SUPPORT. THANK YOU VERY MUCH.

13 (APPLAUSE.)

14 CHAIRMAN KLEIN: THANK YOU, JON, FOR YOUR
15 TREMENDOUS RECORD OF PUBLIC SERVICE AND FINANCE FOR
16 MANY OF THE GOVERNMENTAL ENTITIES IN CALIFORNIA.

17 WITH THAT, I THINK WE WILL TAKE PUBLIC
18 COMMENT. WE'RE GOING TO HAVE BOARD COMMENTS AND
19 PUBLIC -- BOARD DISCUSSION AFTER THE EXECUTIVE
20 SESSION, BUT IT'S APPROPRIATE AT THIS POINT IF THERE
21 ARE MEMBERS OF THE PUBLIC WHO WOULD LIKE TO ADDRESS
22 THE BOARD. DON REED.

23 MR. REED: AS A PATIENT ADVOCATE, I
24 STRONGLY RECOMMEND JONATHAN THOMAS FOR THE
25 CHAIRMANSHIP OF THE INDEPENDENT CITIZENS OVERSIGHT

BARRISTERS' REPORTING SERVICE

1 COMMITTEE OF THE CALIFORNIA STEM CELL PROGRAM. WE
2 ARE FORTUNATE TO HAVE TWO SUCH OUTSTANDING
3 CANDIDATES FOR CHAIR. I CONTACTED BOTH, QUESTIONED
4 THEM AT LENGTH.

5 IN PERSONALITY FRANK LITVACK IS A STRONG
6 LEADER, EXPLOSIVE, CHARISMATIC, AND FUN TO BE
7 AROUND. HIS ANSWERS TO MOST QUESTIONS WERE SHORT,
8 PUNCHY, AND EASY TO FOLLOW.

9 JONATHAN THOMAS, ON THE OTHER HAND, IS
10 QUIET, NOT AN EXCITING SPEAKER, BUT HE HAS A BULLDOG
11 TENACITY WHICH MAKES HIM UNEXPECTEDLY PERSUASIVE.
12 WHEN I ASKED HIM A QUESTION, HE WOULD NOT ONLY
13 ANSWER THE QUESTION, BUT WOULD COME UP WITH POSSIBLE
14 OBJECTIONS TO HIS OWN ANSWER AND ANSWER THOSE AS
15 WELL. HE WOULD NEVER BE DISTRACTED FROM THE ISSUE
16 AT HAND, BUT KEPT COMING BACK TO IT AGAIN AND AGAIN
17 UNTIL EVERY OBJECTION HAD BEEN COMPLETELY MET. HE
18 IS FOCUSED AND DETERMINED, AND HE BASICALLY WORE ME
19 DOWN.

20 FRANK LITVACK IS A HIGHLY SUCCESSFUL
21 ENTREPRENEUR, THE ACTIVE CHAIR OF FIVE COMPANIES.
22 THIS IS EVIDENCE OF HIS SUCCESS IN THE BUSINESS
23 WORLD, BUT IT MAY ALSO BE A POSSIBLE NEGATIVE. WITH
24 THE BEST WILL IN THE WORLD, HIS ENERGIES AND
25 COMMITMENTS WILL NECESSARILY BE DIVIDED WITH FIVE

BARRISTERS' REPORTING SERVICE

1 COMPANIES AS WELL AS WITH THE CIRM.

2 BOB KLEIN ALSO FACED THE PROBLEM OF
3 DIVIDED TIME, BEING CHAIR OF A REAL ESTATE FIRM AS
4 WELL AS LEADING THE CALIFORNIA STEM CELL PROGRAM.
5 HIS ANSWER WAS TO ROUTINELY WORK TO EXHAUSTION,
6 SOMETIMES TO THE POINT WHERE I FEARED FOR HIS
7 HEALTH. THAT IS NOT A TENABLE SOLUTION.

8 JONATHAN THOMAS VIEWS THE JOB OF CHAIR AS
9 A FULL-TIME ONE, REQUIRING HIS 100-PERCENT EFFORT AND
10 COMMITMENT YEAR-ROUND. THAT IS TO MY MIND THE ONLY
11 REALISTIC ASSESSMENT OF THE JOB OF CHAIR. ALMOST
12 CERTAINLY THE NEW CHAIR WILL FACE HUGE FINANCIAL
13 CHALLENGES TO OUR PROGRAM.

14 I ASKED BOTH CANDIDATES IF THE WORST
15 HAPPENED AND THERE WERE NO GENERAL OBLIGATION BONDS,
16 WHAT WILL YOU DO? MR. LITVACK SAID, AND IF I AM
17 MISCHARACTERIZING HIS ANSWER, I HOPE YOU WILL ALLOW
18 HIM TO CORRECT ME, I AM TRYING TO UNDERSTAND SOME
19 VERY COMPLICATED MATTERS HERE. HE SAID, "WITHOUT
20 GENERAL OBLIGATION BONDS, THERE WAS NO WAY TO FUND
21 THE PROGRAM AT ITS CURRENT LEVEL. ANYONE WHO SAID
22 OTHERWISE WAS BLOWING SMOKE."

23 ASKED THE SAME QUESTION, THOMAS SAID HE
24 WOULD FIRST IMPLEMENT A SHORT-TERM PLAN TO STOP THE
25 BLEEDING AND THEN DEVELOP A LONG-TERM FINANCIAL

BARRISTERS' REPORTING SERVICE

1 PLAN. HE LAID IT OUT IN ABOUT A 15-MINUTE ANSWER.
2 I DO NOT PRETEND TO UNDERSTAND IT, BUT IT APPEARED
3 TO BE A MIX OF BONDS, DONATIONS FROM CHARITIES AND
4 FOUNDATIONS, POSSIBLE REVENUES FROM BIOMED, NATIONAL
5 GOVERNMENT CONTRIBUTIONS, OTHER SOURCES OF FUNDING.
6 HE SAID THAT SUCH FUND-RAISING CHALLENGES HAS BEEN A
7 MAJOR PART OF HIS LIFE FOR THE PAST 30 YEARS AND HE
8 WAS PREPARED, IF NECESSARY, TO DO THAT EVERY DAY OF
9 HIS TENURE. HE HAS SHOWN THE ABILITY TO RAISE
10 MASSIVE AMOUNTS OF FUNDING, PROJECTS INVOLVING
11 LITERALLY BILLIONS OF DOLLARS.

12 IN ENTREPRENEURSHIP, FRANK LITVACK IS
13 WONDERFULLY SUCCESSFUL, HAVING DEVELOPED, FOR
14 EXAMPLE, A COMPANY WHICH MANUFACTURED THE MEDICATED
15 HEART STINT AND OTHER VALUABLE PRODUCTS. BUT
16 JONATHAN THOMAS HAS ALREADY DEMONSTRATED THE ABILITY
17 TO PICK A WINNER IN THE BIOMEDICAL WORLD. MANY
18 YEARS AGO WHEN STEM CELL RESEARCH AS AN INDUSTRY WAS
19 JUST GETTING STARTED, HE SHOWED FORESIGHT BY PICKING
20 JUST ONE COMPANY TO SUPPORT, ADVANCED CELL
21 TECHNOLOGY.

22 JONATHAN THOMAS HELPED MIKE WEST RAISE THE
23 CRUCIAL ROUND OF FUNDING HE NEEDED. AND FROM THAT
24 HUMBLE BEGINNING, THE FIELD OF BIOMEDICINE BEGAN.
25 IN A TIME WHEN COMPLICATED FINANCING MAY MEAN

BARRISTERS' REPORTING SERVICE

1 SUCCESS OR FAILURE FOR OUR CALIFORNIA STEM CELL
2 PROGRAM, JONATHAN THOMAS' UNIQUE SKILL SET MAKES HIM
3 THE ESSENTIAL CHOICE. THANK YOU.

4 CHAIRMAN KLEIN: THANK YOU VERY MUCH, MR.
5 REED. IS THERE ADDITIONAL PUBLIC COMMENT? I THINK
6 THAT WE'VE ALL RECEIVED SOME LETTERS OF SUPPORT FROM
7 BOTH PARTIES WHICH WE CAN, BECAUSE THEY'RE PART OF
8 THE PUBLIC DOMAIN -- I THINK WE'VE ALL RECEIVED
9 MEMBERS OF THE PUBLIC'S LETTERS WHICH WE CAN TAKE
10 WITH US INTO EXECUTIVE SESSION. THOSE ARE AVAILABLE
11 TO THE PUBLIC; AND BECAUSE THEY ARE, THEY CAN BE
12 CONSIDERED BY THE MEMBERS OF THIS BOARD.

13 AFTER THE PUBLIC SESSION, WE WILL COME
14 BACK FOR A PUBLIC DISCUSSION OF OUR INDIVIDUAL
15 VIEWS. WE WILL NOT BE REACHING ANY DECISION IN
16 EXECUTIVE SESSION. WE WILL BE REACHING A DECISION
17 ONLY IN THE PUBLIC SESSION. IT IS, AGAIN,
18 EXTRAORDINARY TO HAVE THESE TWO REMARKABLE
19 INDIVIDUALS BOTH WITH A HISTORY OF PUBLIC
20 CONTRIBUTIONS TO MEDICINE, TO THE GREATER PUBLIC
21 POLICY NEEDS OF THIS STATE. IT IS AN EXCEPTIONAL
22 CHOICE WE HAVE TO MAKE.

23 AND WHAT SHOULD BE EMPHASIZED IS THAT WHEN
24 THE BOARD MAKES THAT CHOICE, IT'S GOING TO BE A
25 CHOICE BETWEEN WHAT IS CRITICAL CHARACTERISTICS THAT

BARRISTERS' REPORTING SERVICE

1 THE AGENCY NEEDS AT THIS TIME. IT IS NOT A CHOICE
2 OVER WHO'S QUALIFIED OR NOT QUALIFIED. THEY'RE BOTH
3 EXTRAORDINARILY QUALIFIED. IT IS OUR DEEP PRIVILEGE
4 TO HAVE THEM AS CANDIDATES.

5 SO I WANT TO EMPHASIZE FOR THE PUBLIC THAT
6 ANY ONE ORGANIZATION WOULD BE VERY, VERY
7 APPRECIATIVE OF HAVING ONE OF THESE CANDIDATES
8 BEFORE THEM. FOR US IT IS A REALLY UNUSUAL AND
9 EXTREMELY VALUABLE CONTRIBUTION TO THE FUTURE OF
10 HEALTHCARE IN THE STATE, TO THE FUTURE OF STEM CELL
11 RESEARCH IN THIS STATE, NATIONALLY, AND GLOBALLY TO
12 HAVE THESE TALENTS BEFORE US. THE VERY BEST
13 SOLUTION WOULD BE TO DRAFT BOTH OF THEM, BUT I
14 DIDN'T WRITE INTO THE INITIATIVE THAT WE COULD HAVE
15 CO-CHAIRS. THAT'S MY MISTAKE BECAUSE I DIDN'T
16 ANTICIPATE THIS REMARKABLE OPPORTUNITY BECAUSE
17 EITHER OF THESE INDIVIDUALS WILL BRING A TREMENDOUS
18 AMOUNT TO THE FUTURE OF MEDICINE AND TO THE FUTURE
19 OF STEM CELL RESEARCH IN PARTICULAR.

20 MR. HARRISON, COULD YOU QUOTE THE BASIS ON
21 WHICH WE WILL ADJOURN TO EXECUTIVE SESSION?

22 MR. HARRISON: YES. THE BOARD WILL BE
23 CONVENING IN CLOSED SESSION TO DISCUSS PERSONNEL
24 PURSUANT TO GOVERNMENT CODE SECTION 11226 AND HEALTH
25 AND SAFETY CODE SECTION 125290.30(F)(3)(D).

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN KLEIN: ALL RIGHT. AND COULD THE
2 STAFF TELL US LOGISTICALLY.

3 MS. KING: YOU'RE GOING TO FOLLOW ME TO
4 THE ROOM.

5 CHAIRMAN KLEIN: I SEE. FOLLOW MELISSA
6 KING. STAY CLOSE. ANYONE LEFT BEHIND IS APT TO BE
7 WANDERING IN THE MAZE OF ROOMS HERE. THANK YOU.

8 (THE BOARD THEN CONVENED IN CLOSED
9 SESSION, NOT REPORTED NOR HEREIN TRANSCRIBED.)

10 CHAIRMAN KLEIN: ALL RIGHT. IF WE WILL
11 COME TO ORDER HERE. WE HAVE TWO BOARD MEMBERS WE'RE
12 TRYING TO LOCATE, ONE FROM ISTANBUL, WHO HAS BEEN ON
13 THE PHONE --

14 DR. PIZZO: I'M HERE.

15 CHAIRMAN KLEIN: HI, PHIL. AND KNOWING
16 YOU'RE IN ISTANBUL, PHIL, WE'RE GOING TO, I GUESS,
17 TRY AND GET YOUR VOTE AT THE BEGINNING OF THE ROLL
18 CALL WE TAKE SO THAT WE CAN LET YOU GO. YOU'VE BEEN
19 EXTRAORDINARILY PATIENT.

20 IT IS A GREAT TRIBUTE TO THE QUALITY OF
21 OUR CANDIDATES THE ROBUST DISCUSSION OF THE BOARD.
22 I WANT TO SAY WITH EXTRAORDINARY APPRECIATION FOR
23 THE CANDIDATES, REMARKABLE INDIVIDUALS, THEY DID A
24 FABULOUS JOB IN ANSWERING THE QUESTIONS OF THE BOARD
25 IN THE PERSONNEL SECTION WE WERE JUST IN. IN

BARRISTERS' REPORTING SERVICE

1 ADDITION TO, OF COURSE, TWO PUBLIC SESSIONS PRIOR TO
2 TONIGHT, THE PUBLIC PRESENTATION THEY MADE TONIGHT,
3 WE THINK THEY HAVE REALLY EXHAUSTIVELY GONE THROUGH
4 THIS.

5 OKAY. WE NEED WITH THE HOUR TO MOVE
6 THROUGH THIS QUICKLY. MY SUGGESTION, AND I'VE
7 TALKED TO A QUICK SAMPLE OF DR. LOVE, DR. POMEROY,
8 AND JONATHAN SHESTACK, AND I MADE A SUGGESTION THAT
9 IN THE ROLL CALL, SO THE PUBLIC UNDERSTANDS THE KEY
10 ISSUE IN THE BALANCING OF OUR VOTE, IF EACH PERSON,
11 IF THEY WANT TO, COULD GIVE JUST ONE SENTENCE,
12 PLEASE, NO MORE THAN ONE.

13 MR. TORRES: NO. NO. NO.

14 CHAIRMAN KLEIN: ALL RIGHT. IT LOOKS LIKE
15 CONSENSUS ON THAT ISSUE WAS NOT DEVELOPED BY THE
16 TEST CASE.

17 LET ME JUST THEN SAY THAT WE HAVE TWO
18 FUNDAMENTAL CHOICES. BOTH PEOPLE WOULD BE
19 INCREDIBLE CHAIRS. THE FUNDAMENTAL QUESTION IS AT
20 THIS CRITICAL TIME IN OUR HISTORY, GIVEN THE STATE'S
21 POSITION TODAY, GIVEN THE MEDICAL GOALS WE HAVE TO
22 ACCOMPLISH, WHO EACH BOARD MEMBER FEELS WOULD MAKE
23 THE GREATEST CONTRIBUTION AT THIS CRITICAL MOMENT.

24 WITH THAT, I WOULD LIKE TO FIND WHERE MR.
25 HARRISON IS. JAMES, I THINK WE'RE APPROPRIATELY --

BARRISTERS' REPORTING SERVICE

1 JAMES, I THINK WE'RE APPROPRIATE TO GO THROUGH A
2 ROLL CALL.

3 MR. HARRISON: YES.

4 CHAIRMAN KLEIN: YOU HAVE A SUGGESTION?

5 DR. LOVE: I SUGGEST WE HAVE A MOTION
6 MIGHT BE MADE. I WOULD MOVE THAT WE VOTE FOR ONE
7 CANDIDATE OR THE OTHER TO BE NAMED WITH UP TO 80
8 PERCENT OF TIME COMPENSATION, WHICH WOULD, WITH OUR
9 CALCULATION, BE IN THE RANGE OF \$400,000.

10 CHAIRMAN KLEIN: ANYTHING OVER A HUNDRED
11 FIFTY, IF THAT CANDIDATE TOOK THAT SALARY, WOULD BE
12 PAID BY DONOR FUNDS.

13 DR. LOVE: THAT'S AGREED.

14 CHAIRMAN KLEIN: THAT'S BASED ON THE PRIOR
15 VOTE OF THE BOARD.

16 DR. LOVE: PERFECT.

17 CHAIRMAN KLEIN: OKAY. I WOULD SECOND
18 THAT MOTION.

19 DR. LOVE: SO THE MOTION IS TO VOTE ON OUR
20 CHOICE OF CANDIDATE WITH THE ASSUMPTION THAT THE
21 SALARY COULD BE UP TO 80 PERCENT OF THE TARGET,
22 WHICH WOULD BE APPROXIMATELY \$400,000. AND BOB MADE
23 THE ADDITION THAT ANYTHING OVER 150 WOULD COME FROM
24 THE PHILANTHROPIC FUNDS.

25 CHAIRMAN KLEIN: FROM THE DONOR FUNDS WE

BARRISTERS' REPORTING SERVICE

1 ALREADY HAVE, WHICH IS WHAT THE PRIOR VOTE OF THE
2 BOARD REPRESENTED ON THAT MATTER. ALL RIGHT.

3 MELISSA KING.

4 MR. HARRISON: CHAIR, COULD WE JUST GET A
5 SECOND FOR THAT MOTION?

6 CHAIRMAN KLEIN: I SECONDED.

7 MR. HARRISON: OH, THANK YOU.

8 CHAIRMAN KLEIN: SO WE HAVE PREVIOUSLY
9 TAKEN PUBLIC COMMENT. WE'RE NOT TAKING ADDITIONAL
10 PUBLIC COMMENT AT THIS TIME. AND I BELIEVE WE'RE
11 PREPARED FOR THE ROLL CALL. DO WE NEED ADDITIONAL
12 PUBLIC COMMENT? NO. ALL RIGHT. MELISSA KING, YOU
13 HAVE THE FLOOR.

14 YOU ARE GOING TO VOTE FOR -- YOU'RE GOING
15 TO USE THE NAME OF THE CANDIDATE THAT YOU WANT TO
16 ELECT.

17 MS. SAMUELSON: DO WE NEED TO VOTE TO
18 APPROVE THAT FORMAT OR NOT?

19 CHAIRMAN KLEIN: NO. THAT'S THE MOTION,
20 AND YOU ARE GOING TO VOTE WHICH CANDIDATE YOU WANT.
21 MELISSA KING.

22 MS. KING: ROBERT PRICE.

23 DR. PRICE: FRANK LITVACK.

24 MS. KING: FLOYD BLOOM.

25 DR. BLOOM: JON THOMAS.

BARRISTERS' REPORTING SERVICE

1 MS. KING: DAVID BRENNER.

2 DR. BRENNER: FRANK LITVACK.

3 MS. KING: JACOB LEVIN.

4 DR. LEVIN: JON THOMAS.

5 MS. KING: MICHAEL FRIEDMAN.

6 DR. FRIEDMAN: JON THOMAS.

7 MS. KING: MICHAEL GOLDBERG.

8 MR. GOLDBERG: JON THOMAS.

9 CHAIRMAN KLEIN: MELISSA, SO THAT DR.
10 PIZZO CAN GET OFF THE PHONE, COULD YOU CALL HIM SO
11 WE CAN RELEASE HIM.

12 DR. PIZZO: YES, I AM HERE. AND I WILL
13 VOTE FOR JON THOMAS.

14 MS. KING: THANK YOU, DR. PIZZO.

15 DR. PIZZO: THE LONGEST DISTANCE CASTING
16 VOTE.

17 CHAIRMAN KLEIN: PLEASE USE THE MIC WHEN
18 YOU'RE VOTING. YOU'RE GOING TO SAY JUST ONE NAME.

19 MR. SHESTACK: AND NO SENTENCE.

20 CHAIRMAN KLEIN: NO SENTENCE.

21 MS. KING: SO DR. PIZZO, SINCE YOU HAVE
22 VOTED, BOB IS SAYING THAT YOU CAN GET OFF THE LINE.
23 BUT FROM WHAT I UNDERSTAND, YOU'RE STAYING ON THE
24 LINE; IS THAT CORRECT?

25 DR. PIZZO: YES, I'M GOING TO STAY ON THE

BARRISTERS' REPORTING SERVICE

1 LINE. I'VE GOT A FEW MORE MINUTES AND I WANT TO
2 HEAR WHAT HAPPENS.

3 MS. KING: EXACTLY. THANK YOU.

4 STEPHEN JUELSGAARD.

5 DR. JUELSGAARD: JONATHAN THOMAS.

6 MS. KING. BOB KLEIN.

7 CHAIRMAN KLEIN: JON THOMAS.

8 MS. KING: SHERRY LANSING.

9 MS. LANSING: JON THOMAS.

10 MS. KING: TED LOVE.

11 DR. LOVE: FRANK LITVACK.

12 MS. KING: BERTRAM LUBIN.

13 DR. LUBIN: FRANK LITVACK.

14 MS. KING: SHLOMO MELMED.

15 DR. MELMED: FRANK LITVACK.

16 MS. KING: CLAIRE POMEROY.

17 DR. POMEROY: FRANK LITVACK.

18 MS. KING: FRANCISCO PRIETO.

19 DR. PRIETO: FRANK LITVACK.

20 MS. KING: CARMEN PULIAFITO.

21 DR. PULIAFITO: FRANK LITVACK.

22 MS. KING: ROBERT QUINT.

23 DR. QUINT: JONATHAN THOMAS.

24 MS. KING: DUANE ROTH.

25 MR. ROTH: FRANK LITVACK.

BARRISTERS' REPORTING SERVICE

1 MS. KING: JOAN SAMUELSON.
2 MS. SAMUELSON: FRANK LITVACK.
3 MS. KING: DAVID SERRANO-SEWELL.
4 MR. SERRANO-SEWELL: JONATHAN THOMAS.
5 MS. KING: JEFF SHEEHY.
6 MR. SHEEHY: JONATHAN THOMAS.
7 MS. KING: JON SHESTACK.
8 MR. SHESTACK: JONATHAN THOMAS.
9 MS. KING: OSWALD STEWARD.
10 DR. STEWARD: JONATHAN THOMAS.
11 MS. KING: ART TORRES.
12 MR. TORRES: JONATHAN THOMAS.
13 MS. KING: KRISTINA VUORI.
14 DR. VUORI: FRANK LITVACK.
15 MS. KING: AND THE LAST PERSON WE WOULD
16 NEED TO HAVE VOTE IS MARCY FEIT IF WE CAN GET HER,
17 BUT WE HAVE NOT BEEN ABLE TO REACH HER TO SEE IF SHE
18 WANTS TO REJOIN THE MEETING SINCE SHE LEFT THE
19 MEETING.
20 CHAIRMAN KLEIN: CAN WE BE ADVISED? WHAT
21 IS THE CURRENT VOTE? SO HER VOTE DOES NOT MAKE A
22 DIFFERENCE, BUT I WANT TO CONFIRM WITH THE COUNSEL
23 THAT THEY CONFIRM WITH THE VOTE THAT THE BOARD SEEMS
24 TO BELIEVE EXISTS. WHILE THEY'RE TALLYING THIS, I
25 WOULD SUGGEST THAT WHATEVER THE VOTE COMES OUT TO, I

BARRISTERS' REPORTING SERVICE

1 WOULD SUGGEST THE FRIENDLY AMENDMENT THAT WE BY
2 UNANIMOUS CONSENT THEN JOIN TOGETHER TO SUPPORT
3 WHOEVER IS ELECTED TO SHOW OUR COMMITMENT TO THE
4 CANDIDATE THAT WOULD BE THE CHAIR.

5 MR. HARRISON: THE VOTE IS 14 FOR JON
6 THOMAS AND 11 FOR FRANK LITVACK. SO JON THOMAS IS
7 ELECTED CHAIR.

8 (APPLAUSE.)

9 CHAIRMAN KLEIN: SO I'D LIKE TO SAY
10 THAT --

11 DR. PIZZO: I SECOND MAKING IT UNANIMOUS.

12 CHAIRMAN KLEIN: SO I MADE A MOTION TO
13 MAKE IT UNANIMOUS. DR. PIZZO HAS SECONDED THE
14 MOTION TO MAKE IT NOW A UNANIMOUS ENDORSEMENT OF THE
15 CANDIDATE WHO WAS ELECTED CHAIR TO SHOW THE BOARD'S
16 UNIFIED SUPPORT FOR THAT CANDIDATE. IS THERE ANY
17 DISCUSSION OF THAT MOTION?

18 MS. LANSING: I SECOND IT.

19 CHAIRMAN KLEIN: THE SECOND SECOND WAS
20 SHERRY LANSING ALONG WITH DR. PIZZO. IS THERE ANY
21 PUBLIC COMMENT? CALL THE QUESTION. ALL IN FAVOR.

22 (CHORUS OF AYES.)

23 CHAIRMAN KLEIN: OPPOSED?

24 SO I WOULD LIKE TO SAY THAT FOUR YEARS AGO
25 I WORKED WITH JEANNIE FONTANA, A GREAT BOARD MEMBER

BARRISTERS' REPORTING SERVICE

1 ALTERNATE, TO SEE IF WE COULD RECRUIT FRANK LITVACK
2 FOR PRESIDENT BEFORE WE IDENTIFIED THE AVAILABILITY
3 OF DR. ALAN TROUNSON AS PRESIDENT. AND I SAY THAT
4 BECAUSE I WANT YOU TO UNDERSTAND IN TERMS OF THE
5 PUBLIC THAT'S LISTENING, MAY STILL BE LISTENING TO
6 THIS, THAT I, EVEN THOUGH I VOTED FOR JON THOMAS, IT
7 WAS IN THE CONTEXT OF CHALLENGES FACING US TODAY
8 VERY SPECIFICALLY IN A STATE OF EXTREME STRESS FOR
9 THE STATE OF CALIFORNIA AND THE NATION ON A
10 FINANCIAL BASIS.

11 THE EXTRAORDINARY COMMITMENT AND
12 CONTRIBUTIONS OF FRANK LITVACK TO MEDICINE, I HOPE,
13 WILL AT SOME POINT IN THE NEAR FUTURE BECOME A PART
14 OF THIS BOARD BECAUSE HE HAS A TREMENDOUS AMOUNT TO
15 GIVE. HE'S ALREADY GIVEN A HUGE AMOUNT IN THIS
16 PROCESS. HE'S A REMARKABLE INDIVIDUAL.

17 AND I WOULD LIKE US ALL TO STAND AND GIVE
18 A ROUND OF APPLAUSE TO FRANK LITVACK FOR HIS
19 CONTRIBUTION HE'S MADE TO MEDICINE AND FOR OUR HOPE
20 THAT HE WILL CONTRIBUTE IN THE FUTURE.

21 (APPLAUSE.)

22 CHAIRMAN KLEIN: MR. THOMAS, LIKE THE REST
23 OF YOU WHO ARE IN THE AUDIENCE, WE GAVE THEM A
24 SUGGESTION THAT WE WOULD BE RECONVENING LATER THAN
25 WE HAVE, SO HE IS ON HIS WAY BACK.

BARRISTERS' REPORTING SERVICE

1 FOR BOTH CANDIDATES, HAVING GONE THROUGH A
2 MULTIMONTH PROCESS, IT, I'M SURE, WILL BE A RELIEF
3 TO UNDERSTAND THE OUTCOME AND A GREAT PRIVILEGE FOR
4 HIM TO SERVE AS I HAVE SERVED.

5 WE HAVE -- HOW QUICKLY WILL HE BE BACK?
6 HE'S IN THE LOBBY.

7 MR. GOLDBERG: CAN WE MOVE ANY OTHER
8 BUSINESS? I GOT SOME QUICKIES.

9 CHAIRMAN KLEIN: YOU DO?

10 MR. GOLDBERG: YEAH.

11 CHAIRMAN KLEIN: THE INTENT, I THINK,
12 TONIGHT, MR. GOLDBERG, WOULD BE AFTER WE HAVE
13 WELCOMED MR. THOMAS BACK, WOULD BE TO ADJOURN FOR
14 THE EVENING. I THINK BOTH THE AUDIENCE, THE STAFF,
15 AND THE BOARD --

16 MR. HARRISON: IT'S JUST A REPORT.

17 CHAIRMAN KLEIN: MICHAEL, YOU'RE ON WITH
18 YOUR REPORT.

19 MR. GOLDBERG: I REQUEST PERMISSION TO
20 PROCEED ON ACTON ITEM NO. 10, WHICH IS CONSIDERATION
21 OF A REPORT REGARDING THE IOM STUDY. AND THAT WAS
22 SIMPLY A REPORT BACK, THAT NO BOARD ACTION REQUIRED.

23 I HAD THE OPPORTUNITY TO CONFER
24 EXTENSIVELY AND WROTE UP MY NOTES FOR FEAR THAT IT
25 WOULD BE LATE AT NIGHT BY THE TIME WE GOT TO THIS,

BARRISTERS' REPORTING SERVICE

1 SO ALLOW ME TO READ THEM INTO THE RECORD. I
2 REVIEWED THE SCOPE OF THE WORK FOR THE IOM STUDY AND
3 CONSULTED WITH THE PRESIDENT AND STAFF OF THE OFFICE
4 OF THE CHAIR. AND THEY EACH HAD OBTAINED ADDITIONAL
5 INFORMATION FROM THEIR OWN INTERNAL ORGANIZATIONS AS
6 WELL AS THE INSTITUTE OF MEDICINE REGARDING THE TIME
7 DEMANDS OF THE STUDY ON THE CIRM STAFF.

8 UNLIKE THE EXTERNAL ADVISORY COMMITTEE
9 REPORT FOR WHICH THE CIRM HAD PRIMARY STAFFING
10 RESPONSIBILITY, THE IOM STAFF WILL HANDLE THE VAST
11 BULK OF THE WORK RELATED TO THE STUDY. AND IN ORDER
12 TO MINIMIZE THE BURDEN ON THE PRESIDENT AND THE
13 SCIENCE OFFICE, THE STUDY WILL BE MANAGED THROUGH
14 THE OFFICE OF THE CHAIR. THE OFFICE OF THE CHAIR
15 SHOULD BE ABLE TO HANDLE THE RESPONSIBILITY OF
16 INTERFACING WITH THE IOM; BUT IF IT DETERMINES THAT
17 THERE IS INSUFFICIENT BANDWIDTH, WE CAN CONSIDER AT
18 THE FINANCE SUBCOMMITTEE RETAINING A CONSULTANT TO
19 ASSIST STAFF AND AUGMENTING THE BUDGET
20 APPROPRIATELY.

21 BEGINNING SOMETIME IN JULY, ON A SEPARATE
22 NOTE, THE INSTITUTE OF MEDICINE WILL BE SEEKING
23 NOMINATIONS FROM MEMBERS OF THE CIRM FOR ITS STUDY
24 COMMITTEE. ONCE THE CALL FOR NOMINATIONS IS ISSUED,
25 STAFF IN THE CHAIR'S OFFICE WILL CONTACT BOARD

BARRISTERS' REPORTING SERVICE

1 MEMBERS AND CIRM STAFF FOR INPUT REGARDING POTENTIAL
2 NOMINEES. AND THE STAFF HAS ASKED ME TO BRING THIS
3 TO YOUR ATTENTION SO THAT YOU CAN BEGIN TO THINK OF
4 INDIVIDUALS WHO MIGHT BE SUITABLE MEMBERS OF THE
5 COMMITTEE.

6 CHAIRMAN KLEIN: I WOULD EMPHASIZE THAT
7 THE IOM WILL BE LOOKING FOR INDEPENDENT, OUTSTANDING
8 EXCELLENCE IN THE FIELD, AND RIGOROUS ADHERENCE TO
9 THE IOM'S COMMITMENT TO MAKING CERTAIN THEY'RE FULLY
10 OBJECTIVE. SO THIS IS PEOPLE THAT ARE NOT CLOSELY
11 ASSOCIATED WITH THIS ORGANIZATION.

12 MR. GOLDBERG: RIGHT. AND THIS WAS A
13 CULMINATION OF A REVIEW THAT WAS CONDUCTED POST A
14 BOARD VOTE IN AUGUST OF 2010, I BELIEVE, WHICH
15 AFFIRMED GOING FORWARD WITH THE IOM STUDY. BUT WE
16 WANTED TO MAKE SURE THAT BOTH THE WORKLOAD AND
17 CALENDAR-BASED IMPACT TO THE STUDY WAS OF MINIMAL
18 DISRUPTION TO THE PRESIDENT'S OFFICE AND THEIR STAFF
19 AND ARE VERY RESPECTFUL OF THAT. SO WE WANT TO MAKE
20 SURE THAT, IN FACT, THOSE EXPECTATIONS ARE HONORED.
21 AND PLEASE COME BACK TO ME DIRECTLY IF IT GETS IN
22 THE WAY OF YOUR OTHER IMPORTANT WORK, WHICH IT'S NOT
23 INTENDED TO DO.

24 CHAIRMAN KLEIN: THANK YOU VERY MUCH.

25 MR. THOMAS, THE VOTE WAS 14 TO 11 IN YOUR

BARRISTERS' REPORTING SERVICE

1 FAVOR. WE HAVE GIVEN A STANDING OVATION TO DR.
2 LITVACK AS AN EXTRAORDINARY CANDIDATE. AND AS THE
3 NEXT CHAIR, I WOULD LIKE TO CALL US THE GIVE SAME
4 OVATION TO YOU.

5 (APPLAUSE.)

6 CHAIRMAN KLEIN: SO WITH THAT, THANK YOU
7 FOR THE REPORT. WITH THAT, I THINK WE CAN ADJOURN
8 FOR THE EVENING UNLESS THE BOARD WOULD LIKE TO
9 OVERRULE THE CHAIR, BUT THIS IS A ROBUST, DEDICATED
10 GROUP. AND WE DEEPLY APPRECIATE THE VIBRANCY OF THE
11 DEBATE AND THE PASSION OF DEBATE AND THE UNANIMOUS
12 SUPPORT, MR. THOMAS, THAT THE BOARD THEN PASSED IN A
13 RESOLUTION ENDORSING YOUR CHAIRMANSHIP.

14 SO THE QUESTION, WHAT TIME IS OUR -- 8:30,
15 WHERE, IN THIS ROOM FOR A PRESENTATION. AND IT'S ON
16 IPS CELLS VERSUS EMBRYONIC STEM CELLS. ONE OF THE
17 SPEAKERS RECENTLY WROTE AN ARTICLE FOR *NATURE*. IT'S
18 A VERY TOPICAL, VERY IMPORTANT DISCUSSION. AND I
19 BELIEVE WE HAVE THE OTHER PAPERS PRESENT FOR THE
20 BOARD IN THE MORNING FROM THE OTHER *NATURE* PAPERS
21 AND THE COMMENTARIES ON THIS SUBJECT.

22 THIS IS GOING TO BE AN ONGOING PROCESS OF
23 INFORMATION BECAUSE THERE'S QUITE A BIT OF CONFLICT.
24 AND AS NEW INFORMATION COMES ABOUT, POSITIONS ARE
25 REFINED AND SOMETIMES REVERSED.

BARRISTERS' REPORTING SERVICE

1 MS. LANSING: I ONLY HAVE ONE OTHER THING.
2 I ONLY HAVE ONE OTHER THING TO SAY BECAUSE EVERYBODY
3 WANTS TO GO TO SLEEP. I JUST WANT TO SAY THAT,
4 BECAUSE WE WORKED THROUGH DINNER, WE WERE NEVER ABLE
5 TO HAVE WHAT I WOULD CALL IS NOT A GOODBYE DINNER
6 BECAUSE YOU'RE GOING TO BE WITH US FOREVER, AND TO
7 THANK BOB KLEIN FOR EVERY SINGLE THING THAT HE'S
8 DONE AND HE DESERVES A STANDING OVATION.

9 (STANDING OVATION.)

10 MS. LANSING: BOB, YOU'RE NOT LEAVING.
11 YOU'RE WITH US FOREVER. AND DANIELLE ALSO.

12 CHAIRMAN KLEIN: THERE'S ONE MORE PUBLIC
13 COMMENT. BUT I WOULD LIKE TO SAY IT IS ONE OF THE
14 GREAT PRIVILEGES OF MY LIFE TO BE ABLE TO CONTRIBUTE
15 TO THE PEOPLE OF CALIFORNIA AND THE WORLD AND OUR
16 CHILDREN IN THIS GREAT ENDEAVOR WITH THE MEMBERS ON
17 THIS BOARD, WHICH ARE SUCH EXTRAORDINARY PEOPLE
18 INDIVIDUALLY AND IN THE AGGREGATE UNSURPASSED.

19 MR. REED: BOB, THIS IS THE LAST PUBLIC
20 COMMENT THAT YOU WILL EVER HAVE TO THINK PLEASE BE
21 BRIEF, DON.

22 HOW DO YOU SAY THANK YOU TO SOMEONE WHO
23 CHANGED THE WORLD? THE CALIFORNIA STEM CELL PROGRAM
24 HAS THE GLORY OF A FLAG UNFURLED. BUT HOW DO YOU
25 SAY THANK YOU TO SOMEONE WHO CHANGED THE WORLD?

BARRISTERS' REPORTING SERVICE

1 LIKE A FARMER WHO PLANTS A FIELD IN NEW WAYS,
2 GROWING FOOD FROM EXHAUSTED LAND, YOU BROUGHT LIFE
3 TO A NEW FIELD OF MEDICINE ALTHOUGH OTHERS DID NOT
4 UNDERSTAND.

5 ON A RADIO SHOW ONCE, AN ENEMY OF THE
6 RESEARCH CAME ON THE AIR TO INSULT YOU, BUT YOU
7 WOULD NOT LET THE ANGER TAKE OVER. YOU TALKED TO
8 HIM AS IF HE WOULD CONSULT WITH YOU. VILELY HE
9 COMPARED YOU TO A NAZI, JOSEPH MENGELE, THE ANGEL OF
10 DEATH, BUT YOU SAID, "THANK YOU FOR RAISING THAT
11 IMPORTANT QUESTION." WITHOUT EVEN PAUSING FOR
12 BREATH, YOU EXPLAINED TO HIM WHAT THE RESEARCH
13 REALLY WAS, THE HOPE OF CURE, DAWN, NEW DAY. AT THE
14 END, THE ENEMY SAID, "I NEVER THOUGHT OF IT THAT
15 WAY."

16 BUT IT IS NOT ENOUGH TO THINK ANEW, TO
17 HAVE A LITTLE BIT OF HOPE. RELIEF FOR SUFFERING IS
18 NEEDED, LIKE THROWING A DROWNING MAN A ROPE. YOU
19 RAISED A BILLION FOR DIABETES LONG BEFORE PROP 71,
20 BUT 3 BILLION FOR STEM CELLS, THAT WILL HELP
21 EVERYONE. MANY PEOPLE GAVE THEIR ENERGIES TO PROP
22 71. NOTHING HAPPENS BY ITSELF. BUT AN IDEA WITHOUT
23 A LEADER GATHERS DUST UPON THE SHELF. YOU DREAMED
24 AND DESIGNED IT, RAISED MONEY TO HELP IT GROW,
25 EXHAUSTING DAYS OF LABOR NO ONE WOULD EVER KNOW.

BARRISTERS' REPORTING SERVICE

1 THE VOTERS SAID YES OVERWHELMINGLY, 59.6 PERCENT.
2 CALIFORNIA SUPPORTED CURE RESEARCH. THE MESSAGE WAS
3 PLAINLY SENT.

4 THE BATTLE WAS NOT OVER. OBSTACLES
5 CONFRONTED US EVERY DAY, BUT EVERY DAY THE COMMUNITY
6 FOUGHT BACK. OUR INITIATIVE WAS HERE TO STAY. THE
7 MAGNIFICENT BOARD OF GOVERNORS, INDEPENDENT CITIZENS
8 OVERSIGHT COMMITTEE STRUGGLED WITH NEAR IMPOSSIBLE
9 DECISIONS IN LIGHT OF DAY FOR ALL TO SEE. AT THE
10 CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE,
11 NARROW OPENING TO THAT KING STREET ADDRESS, THE
12 STAFF OF CIRM BRINGS THE PROGRAM TO LIFE, QUIET
13 HEROISM, MUSCLING TOWARDS SUCCESS, AND 12 NEW
14 BUILDINGS HAVE SPRUNG UP, SHINING CENTERS OF
15 TOMORROW WHERE SCIENTISTS WORK TO SAVE LIVES, EASE
16 SUFFERING, AND DIMINISH SORROW.

17 THERE IS NO WAY TO THANK YOU PROPERLY FOR
18 THE SHINING PROP 71 EXCEPT TO PLEDGE WE WILL PROTECT
19 IT, CONTINUING WHAT WAS SO NOBLY BEGUN. YOU BROUGHT
20 A STATE TOGETHER, BOB. YOUR VOICE INSPIRING CALL.
21 THE PEOPLE IN THIS ROOM STAND UNITED. WE LOVE YOU
22 ONE AND ALL.

23 (APPLAUSE.)

24 CHAIRMAN KLEIN: I THINK WE HAVE A
25 CANDIDATE FOR POET LAUREATE OF THE CALIFORNIA

BARRISTERS' REPORTING SERVICE

1 INSTITUTE OF REGENERATIVE MEDICINE.

2 I WOULD LIKE TO SAY THAT TOMORROW THEY'VE
3 ASKED ME, BEFORE WE SWEAR IN THE NEW CHAIR, TO MOVE
4 THROUGH SOME ORDERS OF BUSINESS SO THAT WE DON'T PUT
5 THE NEW CHAIR IN A CRISIS WITH NOT ENOUGH TIME TO
6 FINISH SOME CRITICAL ITEMS THAT HE HASN'T HAD THE
7 CHANCE TO BRIEF HIMSELF ON. SO I WILL SEE YOU
8 TOMORROW, AND I WILL ASK THAT TONIGHT WE ALSO THINK
9 ABOUT DR. TROUNSON, THE SCIENTIFIC STAFF, THE
10 LAWYERS, THE ADMINISTRATIVE STAFF FOR THIS AGENCY.
11 THESE ARE EACH HEROES IN MY LIFE BECAUSE THEY'RE THE
12 ONES THAT MADE THIS HAPPEN ALONG WITH THE GREAT
13 SCIENTISTS AND PHYSICIAN SCIENTISTS OF CALIFORNIA
14 WHO ARE HONORING OUR COMMITMENT TO PATIENTS,
15 PATIENTS WHO DEPEND UPON US FOR THE HOPE FOR SEVEN
16 AREAS OF CRITICAL CHRONIC DISEASE AND INJURY.

17 SO THANK YOU TO THE STAFF. THANK YOU TO
18 THE SCIENTISTS. IT IS ON YOUR SHOULDERS THAT WE
19 STAND. AND ON YOUR SHOULDERS WE'VE MADE PROGRESS
20 THROUGH CHANGING THE FUTURE OF HUMAN SUFFERING. SO
21 THANK YOU AND GOOD NIGHT.

22 (APPLAUSE.)

23 (THE MEETING WAS THEN CONCLUDED AT
24 10:42 P.M.)

25

BARRISTERS' REPORTING SERVICE

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

SHERATON SAN DIEGO HOTEL AND MARINA
1380 HARBOR ISLAND DRIVE
SAN DIEGO, CALIFORNIA

ON

WEDNESDAY, JUNE 22, 2011

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152
BARRISTER'S REPORTING SERVICE
1072 BRISTOL STREET
SUITE 100
COSTA MESA, CALIFORNIA
(714) 444-4100